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ABSTRACT
The vast majority of studies on attention-deficit/hyperactivity disorder (ADHD) are based
on samples with inherent age, sex, and referral biases. Therefore, the current study used
population-based data to 1) estimate the prevalence of adult ADHD (ADHD screening
status as well as previous diagnosis and medication use using an ADHD screener) and cooccurring psychiatric distress and substance use in Ontario 2) examine the sex differences
in ADHD screening status and co-occurring psychiatric distress and substance use and 3)
model ADHD screening status as a risk factor for psychiatric distress using the 2011
cycle of the Centre for Addiction and Mental Health Monitor. A positive ADHD screen
was significantly associated with psychiatric distress and substance use; however the
majority of those with a positive ADHD screen did not exhibit these issues. Symptom
overlap and lack of diagnosis and treatment may have contributed to the findings in this
sample. Importantly, the effect of age must also be accounted for in future studies where
sample size permits.
Keywords: ADHD, Adult, Ontario, CAMH Monitor, Prevalence, Sex, Psychiatric
distress, Antidepressants, Anti-anxiety medications, and Substance use
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Chapter 1: ADHD Prevalence, Aetiology and Concurrent Disorders
1.1 What is ADHD?
Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurobiological disease
characterized by difficulties with attention, motor activity, and impulse control
(American Psychiatric Association, 1994). The diagnostic criteria for ADHD in North
America are outlined in the Diagnostic and Statistical Manual of Mental Disorders IV
(DSM-IV). This diagnosis of ADHD requires that six or more of the symptoms of
inattention, hyperactivity, or impulsivity cause considerable impairment in two or more
settings and have persisted for the last six months to an extent that is maladaptive and
inconsistent with developmental level (APA, 1994). Furthermore, these symptoms must
have occurred before the age of seven to warrant a diagnosis (APA, 1994). The clinical
heterogeneity of ADHD is recognized in the DSM-IV by three subtype classifications
based on primary symptom category endorsement. These subtypes include the
predominantly inattentive subtype (ADHD-I), the predominantly hyperactive-impulsive
subtype (ADHD-H) and a combined subtype (ADHD-C) (APA, 1994).
ADHD is a controversial disorder in part due to its aetiological complexity, but
also because conceptualizations of the disorder have varied drastically since its inception
(Toplak, Connors, Shuster, Knezevic, & Parks, 2008). Gomez and colleagues (1999)
posit that no other disorder has been subject to as much renaming and reconceptualization
within different versions of the DSM. Since its clinical emergence in 1902 (Still, 1902),
ADHD has been designated by a myriad of terms including: minimal brain damage,
hyperkinetic syndrome, hyperactivity and attention-deficit disorder (ADD) among others.
The most notable shift in the conceptualization of ADHD occurred in the 1970s, when
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attention dysfunction was presented as the defining feature of the disorder (Douglas,
1972). Although based on a progressively larger empirical foundation, the evolution of
the nomenclature for the disorder from DSM-III to DSM-IV has broadened the case
definition so that more individuals are diagnosed with ADHD. Furthermore, these
changes reflect an adaptation from earlier definitions that stressed a more narrow focus
on motor activity, to the current conceptualization which emphasizes difficulty with
sustained attention and deficits in the regulation of cognitive functioning (Faraone et al.,
2000).
1.2 Aetiology
The aetiology of ADHD is unknown; recent findings suggest that a strong genetic
link and environmental factors interact in the genesis of the disorder.
Compelling evidence of the heritability of ADHD is derived from family, adoption, and
twin studies, as well as from neurophysiological and molecular genetics research.
The rate of ADHD in the biological relatives of individuals with ADHD is
significantly higher in comparison to the rates of ADHD in families of children without
ADHD (e.g., Faraone, Biederman, & Friedman, 2000). Specifically, 30-35% of the
siblings of ADHD-diagnosed individuals also met criteria for ADHD, with a relative risk
for ADHD that was approximately five times that of the estimated population prevalence
of the disorder. Furthermore, when analyses were restricted to those with ADHD
persisting into adolescence or young adulthood, the risk increased several fold (reviewed
in Faraone et al., 2000). Although the heritability estimates for ADHD are not as high as
those proposed for autism, they are however substantially higher than those estimated for
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other highly heritable disorders such as bipolar affective disorder and schizophrenia
(NIMH Genetics Workgroup, 1997).
Results from adoption studies showed that the biological siblings and parents of
non-adopted children with ADHD exhibited significantly higher rates of ADHD and
associated attention problems, whereas adoptive parents of individuals with ADHD were
not significantly different from parents of comparison children without ADHD (reviewed
in Willcut, 2005).
Further evidence of the biological underpinnings of the disorder come from
studies of monozygotic and dyzygotic twins. ADHD twin studies have found that the
concordance rate was significantly higher among monozygotic pairs (58% - 82%) than
same-sex dizygotic pairs (31% - 38%) (Levy, Hay, McStephen, Wood, & Waldman,
1997; Levy, McStephen, & Hay, 2001; Sherman, McGue, & Iacono, 1997; Willcutt,
Pennington, & DeFries, 2000). In addition, Willicut (2005) found that the mean
heritability across a number of large-scale population-based twin studies was 73%,
demonstrating that individual differences in ADHD symptoms are largely attributable to
genetic influences.
Neurophysiological research indicates that the prefrontal cortex (specifically the
dorsolateral prefrontal cortex and the orbital frontal cortex), the basal ganglia (striatum),
the caudate nucleus, and the cerebellum play a significant role in ADHD because of their
involvement in complex processes that regulate behaviour (Castellanos, 1997; Seidman,
Valera & Makris, 2005).
The primary deficits in ADHD typically involve executive function. Executive
function refers to a variety of cognitive processes that are implicated in managing other
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cognitive functions (Elliot, 2003). Executive function includes planning, working
memory, attention, problem-solving, inhibition, and task switching (Monsell, 2003).
Therefore, areas primarily responsible for these functions have been implicated in the
disorder (Seidman et al., 2005). Specifically, under-activation in the dorsolateral
prefrontal cortex and the orbital frontal cortex has been found to be responsible for
inattention, disinhibition, and hyperactivity in ADHD (Giedd, Blumenthal, Molloy &
Castellanos, 2006). Functional neuroimaging studies of ADHD support this theory, as
these studies suggest hypoactivation in prefrontal neural processing in individuals with
ADHD (Silberstein, Farrow, Levy, Pipingas, Hay & Jarman, 1998).
Another hypothesis regarding the aetiology of ADHD suggests that prenatal and
perinatal damage to the striatum, an area within the basal ganglia, is responsible for
deficits in executive function as the circuitry within the basal ganglia is essential for
executive processes (Lou, 1996; Seidman et al., 2005). The striatum has been found to be
particularly vulnerable to complications during pregnancy and delivery, premature birth,
and low birth weight which have been found to occur at higher than normal rates in
ADHD (Sprich-Buckminster, Biederman, Milberger, Faraone & Krifcher Lehman, 1993).
Furthermore, animal studies of experimentally-induced striatal lesions have demonstrated
that insult to this area produces hyperactivity and poor performance on working memory
and response inhibition tasks akin to that seen in ADHD (Alexander, DeLong & Strick,
1986). Lastly, stimulant medications used to treat ADHD have been found to affect the
striatum, possibly via the rich source of dopaminergic synapses in this area (Dougherty,
Bonab, Spencer, Rauch, Madras & Fischman, 1999; Volkow, Fowler, Wang, Ding &
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Gatley, 2002). Taken together, these results implicate striatal anomalies in the
pathophysiology of ADHD.
The cerebellum was originally thought to be primarily involved with motor
control; however findings over the past 20 years indicate that the cerebellum is also
involved in cognitive and affective processes. Interestingly, Middleton and Strick (2001)
have shown cerebellar-cortical connections that provide an anatomic substrate for a
cerebellar-prefrontal circuit in the pathophysiology of ADHD. In addition, reduced
cerebellar volume has also been found in studies of ADHD children and cerebellar
volume has been shown to be significantly and negatively correlated with attention
problems (Seidman et al., 2005). Therefore, anomalies in the cerebellum are also thought
to be characteristic of the pathophysiology of ADHD.
Dysregulation in catecholamine neurotransmission is implicated in the
pathophysiology of ADHD (Faraone & Biederman 2002). Converging evidence from
animal studies of behaviour and biochemistry (Gainetdinov, Wetsel, Jones, Levin, Jaber
& Caron, 1999; Giros, Jaber, Jones, Wightman & Caron, 1996; Jaber et al., 1999),
neuropharmacological studies of the effectiveness of methylphenidate in reducing
symptoms of hyperactivity and inattention, and neuroimaging studies demonstrating the
association of ADHD with executive functions and the fronto-striatal pathways
dependent upon dopamine transmission (Dougherty et al. 1999; Krause, Dresel, Krause,
Kung & Tatsch, 2000), have made the dopaminergic pathways and their candidate genes
areas of intense study in ADHD (Banaschewski, Becker, Scherag, Franke & Coghill,
2010).
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Molecular genetics research has found limited but suggestive evidence of a causal
relationship between DNA variants in serotonin and dopamine transporter genes
SLC6A3, DRD4, DRD5, HTR1B, SLC6A4 and SNAP25 and ADHD (Banaschewski et
al., 2010). As such, although family, adoption, and twin studies implicate a genetic
component in the aetiology of ADHD, no specific DNA variants have been identified as
sufficient risk factors for the development of the disorder.
Recent studies have examined the existence of rare Copy Number Variants
(CNVs) in individuals with ADHD. CNVs are rare genetic duplications or deletions that
are likely to directly affect gene function. A study by Williams and colleagues (2010)
demonstrated that individuals with ADHD had a significantly higher burden of rare
CNVs than controls. Although several rare variants have been found, a confirmed
common variant for ADHD has yet to be discovered. Therefore at present, it can be
concluded that a substantial number of DNA variants may be implicated in the disorder.
The genetic findings to date underscore the biological basis of the disorder, however
future research using large sample sizes akin to those used in studies of schizophrenia and
bipolar disorder are necessary to establish genome-wide significance as hard evidence of
genetic causation in ADHD.
Genetics alone are not sufficient to produce ADHD and several environmental
factors have also been proposed as possibly contributing to the aetiology of the disorder.
Risk factors such as diet (Feingold, 1976), ineffective parenting (Willis & Lovaas, 1977),
and television exposure (Christakis et al., 2004) were proposed; however, these
hypotheses have since been disproven by later studies (Kavale & Forness, 1983; Obel
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Henriksen, Dalsgaard, Linnet, Skajaa, & Thomsen, 2004; Stevens & Mulsow, 2006;
Wolraich, Wilson & White, 1995).
Environmental factors that have demonstrated sufficient evidence of a temporal
association and/or suggestive evidence of a causal relationship with ADHD include
cerebral hemorrhage and traumatic brain injury (Max et al., 2002; Herskovits,
Megalooikonomou, Davatzikos, Chen, Bryan & Gerring, 1999), low birth weight
(Breslau et al., 1996), maternal smoking and alcohol use during pregnancy (Mick,
Biederman, Faraone, Sayer, & Kleinman, 2002; Milberger, Biederman, Faraone, Guite &
Tsuang, 1997), exposure to toxins (reviewed in Banerjee, Middleton & Faraone, 2007),
maltreatment and emotional trauma (Famularo, Kinscherff & Fenton , 1992), and family
psychosocial adversity (Milberger et al., 1997 ). However, these factors may interact with
parental genotype as parents who have ADHD may be more likely to smoke, give birth
prematurely, use other substances, neglect their children, and face psychosocial adversity.
Because ADHD is a complex disorder, its aetiology most likely involves the
heritability of specific genes and DNA variants, environmental exposures and the critical
timing of such exposures. Importantly, aetiological mechanisms include not only biology
and the environment, but synergistic interactions between these factors which are much
more challenging to identify. Biederman and Faraone (2005) suggested that the
developmental pathophysiology of ADHD can best be conceptualized as consisting of a
genetic predisposition to the disorder and early environmental insults which lead to
fronto-subcortical catecholamine dysfunction and ADHD in childhood. ADHD in turn
may lead to later environmental exposures such as substance use and psychosocial
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adversity which lend to the secondary effects of the disorder such as low-self-esteem,
school failure, social disability and ultimately in unremitting cases, adult ADHD.
1.3 ADHD Prevalence
ADHD often emerges in childhood and is usually apparent during the first few
years of grade school (Goldman, Genel, Bezman & Slanetz, 1998) with the majority of
ADHD diagnoses being made between 4 to 12 years of age (Biederman & Faraone,
2005). ADHD had been deemed, “the most common neurobehavioral disorder of
childhood” (American Academy of Pediatrics, 2000) as children with ADHD comprise
up to 50% of some child psychiatric populations (Cantwell, 1996). The DSM-IV states
that the prevalence of ADHD is about 3 to 5% among school-age children (APA, 1994).
This estimate, although frequently cited, is poorly documented. For example, three
reviews of ADHD in pediatric clinical settings reported prevalence estimates ranging
from 1.7% to 17.8%, 3% to 6% and 4% to 12%, respectively (Brown et al., 2001; Elia,
Ambrosini & Rapoport, 1999; Goldman et al., 1998). Furthermore, epidemiological
studies that applied the DSM-IV criteria to school populations have yielded prevalence
estimates as high as 11% to 16% (Cantwell, 1996). In their meta-analysis of the
epidemiology of ADHD, Polanczyk and Rhode (2007) found that the worldwide
prevalence of ADHD is around 5.29% for children and adolescents and 4.4% in adults.
Prevalence estimates of adult ADHD worldwide range from 1.0% to 7.3%
(Almeida Montes, Hernandez Garcıa & Ricardo-Garcell, 2007; Barbaresi et al., 2004;
Bitter, Simon Balint, Meszaros & Czobor, 2012; DuPaul et al., 2001; Faraone &
Biederman, 2005; Fayaad et al., 2007; Gadow, Sprafkin, Schneider, Nolan, Schwartz &
Weiss, 2007; Heiligenstein, Conyers, Berns & Miller, 1998; Kooij, Buitelaar, van den
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Oord, Furer, Rijnders & Hodiamont, 2005; Medina-Mora et al., 2005; Murphy &
Barkley, 1996; Weyandt, Linterman & Rice, 1995) and from approximately 4 to 5% in
the United States (Faraone & Biederman, 2005). Yet due to the use of convenience
samples with low mean ages and gender biases, results from many of these studies cannot
accurately be extrapolated to the general population. Higher prevalence rates have also
been documented among urban compared to rural communities (Offord, Boyle &
Szatmari, 1987), although it is uncertain whether these findings indicate greater access to
mental health and medical care in urban populations. Nonetheless, the substantial
variation in ADHD prevalence rates appears to be largely affected by the methodological
characteristics of these studies. Furthermore, Anderson (1996) states that standardized
diagnostic criteria and methodology can reduce the variability in reported prevalence,
even in studies of highly diverse populations such as the United States, China, and
Kenya.
1.4 ADHD in Adults
Because ADHD was originally conceptualized as a disorder of childhood, debate
exists around the legitimacy of the disorder in adults. However growing evidence
supports the persistence of symptoms into adulthood. Longitudinal studies of individuals
diagnosed with ADHD in childhood demonstrate that ADHD persists into adulthood in a
substantial proportion of cases (Barkley, Fischer, Smallish, & Fletcher, 2004; Mannuzza,
Klein, & Moulton, 2003; Weiss & Hechtman, 1993). Follow-up studies of children with
ADHD estimate that 10 to 66% of individuals experience symptoms of the disorder
throughout adolescence and into adulthood (Gittelman et al. 1985; Manuzza et al. 1993;
Weiss, 1985; Weiss et al. 1985; Weiss & Hechtman, 1992). Furthermore, approximately
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30-60% of children with ADHD will continue to meet full criteria for the disorder as
adults (Biederman, 1998; Biederman, Mick & Faraone, 2000; Manuzza et al. 1993;
Weiss, 1985; Weiss & Hechtman, 1992). Moreover, a meta-analysis of these studies
revealed that as many as 65% of children with ADHD will show symptoms of sufficient
severity to impair functioning in adulthood (Faraone, Biederman, & Mick, 2006).
Corroborating evidence of the legitimacy of the disorder in adulthood comes from
findings from neurobiology and genetics that mirror results seen in children (Faraone,
2004). Specifically, ADHD adults show evidence of structural and functional brain
anomalies akin to those found in ADHD children (Paloyelis, 2007; Valera, Faraone,
Murray & Seidman, 2007). ADHD adults share similar neuropsychologic deficits,
executive dysfunction and familial transmission as ADHD youth (Barkley, Murphy &
Fischer, 2008; Manuzza et al., 1993; Faraone, Doyle, Lasky-Su, Sklar, D'Angelo,
Gonzalez-Heydrich, Kratochvil, et al., 2008). ADHD adults also present similar clinical
features as ADHD children and have been found to respond to the same pharmacological
interventions used with younger populations (Faraone & Glatt, 2010). Finally, ADHD
adults also exhibit psychiatric difficulties analogous to those found among their younger
counterparts (Barkley, Murphy & Fischer, 2008).
Diagnosis of adult ADHD is particularly challenging. A developmental shift in
the disorder in adulthood has been suggested, whereby overt hyperactivity is reduced but
inattention and disorganization persist (Bierderman, Mick & Faraone, 2000; Faraone,
Bierderman, Spender, Wilens, Seidman, Mick & Doyle, 2000). As such, the DSM-IV
criteria for ADHD may not be applicable to adults because the type and number of
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symptoms listed in the current edition (DSM-IV) may not accurately reflect adult
behaviours (Ingram, Hetchman & Morgenstern, 1999).
Furthermore, a diagnosis of ADHD requires that symptoms be present before the
age of seven (APA, 1994). Therefore, in order to be diagnosed as an adult, individuals
must provide corroborating evidence from childhood either via parents, siblings,
pediatricians or childhood teachers or they must retrospectively report experiencing
symptoms during childhood. However, numerous studies have revealed discrepancies in
self-reports of ADHD symptoms relative to other informants (Barkley, Fischer, Smallish,
& Fletcher, 2002). These discrepancies may result from deficient self-awareness or a
positive illusory bias- the tendency toward positive self-perception (Knouse, Bagwell,
Barkley, & Murphy, 2005) often seen among ADHD children (Owens, Goldfine,
Evangelista, Hoza, & Kaiser, 2007). Nonetheless, self-report measures are a commonly
used method for diagnosing ADHD in adults.
As previously mentioned, prevalence rates for adult ADHD vary considerably
between studies due to the characteristics of the sample and study methodology. Despite
the fact that interest in adult ADHD has increased in recent years, it remains relatively
under-investigated in Canada. Consequently, the prevalence of adult ADHD in Canada is
currently unknown.
1.5 Sex and ADHD
Most of what we know about ADHD at present is based on studies of boys
(Gershon, 2002). Much less is known about adult manifestations of this disorder, and
even less is known about how symptoms and outcomes may be differentially expressed
by sex in adulthood. Clinical diagnostic studies in children indicate that a considerable
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discrepancy exists in the diagnosis of ADHD in childhood. The gender ratio comparing
males to females has ranged anywhere from 2:1 to 9:1 (Biederman, Faraone, Keenan,
Knee & Tsuang, 1990; Gittelman, Mannuzza, Shenker & Bonagura, 1985; Weiss,
Hechtman, Milroy & Perlman, 1985). More recent prevalence estimates come from a
nation-wide telephone survey conducted in 2003-2004 that indicated the prevalence of
ADHD was 14% in 10-year-old boys and 6% in 10-year-old girls, with stimulant
medication use rates of 9% and 4%, respectively (Swanson et al., 2007).
However, other recent epidemiological evidence suggests that prevalence may be
similar in both sexes. Diagnosis of ADHD in a representative national US survey of
adults found an odds ratio of 1.6 between men and women, reflecting 5.4% of men and
3.2% of women (Kessler et al., 2006), indicating an equalization of the sex distribution of
the disorder in adulthood (Kessler et al., 2005; McGough et al., 2005). A representative
student survey conducted in Atlantic Canada included an ADHD screening and found a
non-significant difference between girls and boys, with a prevalence of 6.2% and 5.9%,
respectively (Poulin, 2007).
The vast majority of the research on sex and ADHD was conducted with
clinically-referred samples. Therefore, the preponderance of males versus females
possibly reflects the higher number of referrals for males with ADHD, due to their
greater propensity towards disobedience in educational settings (Gershon, 2002). Females
with ADHD however tend to display inattentive and therefore less disruptive behaviour
than males with ADHD. Since disruptive behaviour is likely to be a motivating force
behind clinic referrals, girls are more liable to be overlooked, resulting in an
underrepresentation of females in clinical samples (Gaub & Carlson, 1997). Thus,
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clinically-referred girls likely display particularly disruptive behaviour, but may not
accurately represent the majority of women with ADHD (Gershon, 2002). As Miller and
Leger (2003) state, “recent scholarship regards the association of males with ADHD as
largely mythic, proposing that the clinical imbalance derives from under-diagnosis
among girls and a similar failure to identify ADHD in older women”.
Thus, the research suggests contradictory findings: some studies found higher
prevalence of ADHD males to females, while other studies found no sex differences in
prevalence of ADHD. Only one Canadian non-clinical study, a high school survey, was
found which indicated a non-significant difference favouring girls over boys.
1.6 ADHD and Concurrent Disorders
Whether ADHD stands alone as a distinct disorder is unclear, as ADHD
symptoms have been found to converge with other forms of psychopathology (Furman,
2005). The difficulty distinguishing ADHD from other pathology indicates that ADHD
may not be a distinct neurological or psychological disease entity and mayrepresent a
common behavioural pathway for a plethora of emotional, psychological and/or learning
difficulties (Furman, 2005). In young people, ADHD has been found to co-occur with
anxiety disorders in 25-35% of cases, mood disorders in 20% of cases, and oppositional
defiant disorder (ODD) and conduct disorder (CD) in 25-50% of cases (Steele, Jensen &
Quinn, 2006). ADHD therefore, often co-occurs with other psychiatric disorders in child
populations.
Interestingly, high levels of psychiatric difficulties in ADHD adults parallel
findings from ADHD children. Studies consistently show that adult ADHD frequently cooccurs with mood, anxiety, substance use and antisocial personality disorders (Biederman
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et al., 1991a; Downey, Stelson, Pomerleau, & Giordani, 1997). Shekim and colleagues
(1990) studied a group of 56 adults who met the DSM-III-R criteria for ADHD. Of this
sample, only 14% met criteria solely for ADHD; 20% had one comorbid diagnosis, 29%
met criteria for two other diagnoses, 11% met criteria for three additional diagnoses, and
as many as 33% suffered from four other diagnoses. As such, converging results indicate
that ADHD commonly co-occurs with other mental disorders among both children and
adults.
1.7 Internalizing Disorders: Mood and Anxiety Disorders
1.7.1 ADHD and Depression in Children. Depression is a mental state
characterized by feelings of sadness, low mood and anhedonia, accompanied by reduced
energy (APA, 1994).The association between ADHD and depression in children has been
demonstrated across a number of studies (reviewed in Angold, Costello, & Erkanli, 1999)
with up to 47% of clinical ADHD children cases having this comorbidity (Wilens et al.,
2002). Moreover, a substantial overlap between ADHD and major depressive disorder
(MDD) has been reported from both population (Anderson, Williams, McGee & Silva,
1987; Bird et al., 1988) and clinical studies (Biederman, Faraone, Keenan, Knee &
Tsuang, 1990; Jensen et al., 1988; Woolston, Rosenthal, Riddle, Sparrow, Cicchetti &
Zimmerman, 1989). Reviews of the literature have concluded that the two disorders cooccur more frequently than expected by chance alone and that their relationship is bidirectional as relatively high rates of ADHD and depression have been reported in studies
of both mood disorders and ADHD (Angold & Costello, 1993; Biederman et al., 1992;
Angold, Costello & Erkanli, 1999; Bird, Gould, & Staghezza, 1993; Butler, Arrendondo,
& McCloskey, 1995; MTA Cooperative Group, 1999).
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The association between ADHD and depression has been demonstrated in studies
of clinically referred children and adolescents as well as in community samples. For
example, results from a study by LeBlanc and Morin (2004) indicated that children 7-12
years of age with ADHD reported significantly higher scores on a self-report measure of
depressive symptoms (n = 68). A study by Nolan and colleagues (1999) used parent and
teacher checklists based on DSM-IV diagnostic criteria to obtain information about
depressive symptoms in 222 clinic-referred children between the ages of three and 18
years of age. Results from this study showed that ADHD was significantly associated
with MDD according to both parent and teacher reports (Nolan, Volpe, Gadow &
Sprafkin, 1999). Souza, Pinheiro, Denardin, Mattos and Rohde (2004) examined ADHD
and comorbid depression in two clinical samples consisting of three to 17 year olds and
found that prevalence rates were 10.3% and 11.4% respectively. As such, studies
examining clinical samples demonstrate high rates of ADHD and comorbid depression.
The association between ADHD and depression has also been demonstrated in
community samples. Romano and colleagues (2005) studied a community sample of
adolescents (n = 1,201) and found that 2.9% met diagnostic criteria for both ADHD and
MDD. Also, based on parent reports in a community sample of 7,231 children attending
grades one to four, Blackman, Ostrander and Herman (2005) found that 10% of
participants with ADHD also had depression; hence having a diagnosis of ADHD
increased the risk of having depression. Furthermore, in their study comparing children
and youth with ADHD from both clinic (n = 763) and community (n = 1,896) samples,
Bauermeister and colleagues (2007) found that the rates of depression were 9.27% and
22.73% in the community and clinic samples, respectively. Therefore, the concurrence of

16
ADHD and depression, although higher among clinical samples, is also apparent in
community samples.
1.7.2 ADHD and Depression in Adults. ADHD has also been found to be
associated with clinical depression in adults. Similar to studies of ADHD children,
studies of ADHD adults have reported high levels of depression with a correspondingly
wide range of prevalence rates in both clinic and epidemiological samples. A prospective
follow-up study comparing individuals referred for clinical assessment in childhood (n =
147) to community controls (n = 71), found that adults with ADHD were at a greater risk
for developing MDD, with a prevalence rate of 26% versus 12% in community controls
(Fischer, Barkley, Smallish & Fletcher, 2002). A study conducted by Sobanski and
colleagues (2007) compared clinic-referred adults with ADHD (n = 70) to age and sex
matched controls (n = 70) to ascertain the difference in prevalence rates for Axis-I
disorders. Results showed that the prevalence of depression was 55% in adults with
ADHD versus 25.3% in controls (Sobanski et al., 2007). Cumyn, French and Hechtman
(2009) also compared ADHD to non-ADHD adults (n = 477) and found that the ADHD
group had significantly higher rates of MDD with a prevalence of 19.2%.
Furthermore, using a nationally representative survey of adults (n = 9282),
findings from the National Comorbidity Survey Replication demonstrated that 38.3% of
ADHD adults had a concurrent mood disorder (Kessler et al. 2006). Concurrent ADHD
and depression is related to poor long-term prognosis and psychiatric impairment
(Biederman, Faraone, Keenan, & Tsuang, 1991b; Biederman, Faraone, Milberger, Guite,
Mick & Chen, 1996; Ollendick & King, 1994) including higher rates of suicide
(Biederman et al., 1991; Lewinsohn, Rohde, & Seeley, 1994).

17
As indicated by the above studies, prevalence rates for comorbid ADHD and
depression range extensively with higher rates found in clinical samples (Biederman et
al., 1992; Biederman, Faraone, et al., 1991b; Biederman et al., 1987; Butler, Arrendondo
& McCloskey, 1995). Yet it is likely that clinical cases are more symptomatic and more
impaired than the general population, resulting in a referral bias for more troubled
individuals. Another reason for the considerable discrepancy in prevalence rates is the
use of various measures and cut off scores for determining the presence of ADHD and
depression. Some studies use third party reports in the form of checklists and
questionnaires, whereas others use standardized interviews with the individual, parent, or
teacher, and still others use self-report questionnaires or combinations of these measures.
Therefore, prevalence rates show substantial variability across studies not only due to
differing study populations, but also due to the lack of consistent measures and varying
disease thresholds.
1.7.3 ADHD and Anxiety Disorders in Children.
In addition to mood disorders, anxiety disorders are also particularly prevalent
among individuals with ADHD. Anxiety disorders refer to those disorders for which
severe anxiety is a salient and ongoing symptom (APA, 1994). Pediatric studies of
clinical and community samples from the United States have documented a concurrence
between anxiety disorders and ADHD. Results from a review of the literature prior to
1998 showed that 15% to 35% of children with ADHD also exhibit considerable anxiety
(Pliszka, Carlson & Swanson, 1999).
Several prevalence rates have been documented in referred pediatric samples.
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Based on parental reports of children clinically referred for ADHD, the Multimodal
Treatment Study of Children with ADHD Cooperative Group (1999b) found that, 33.5%
of children with ADHD had comorbid anxiety disorders. A study by Karustis and
colleagues (2000) examined the prevalence of comorbid anxiety using parent, teacher and
child self-reports in a clinical sample of children aged 7-12 years (n = 125). Results from
this study showed that the prevalence of comorbid anxiety was approximately 17%
(Karustis, Power, Rescorla, Eiraldi & Gallagher 2000).
Similar rates of comorbid ADHD and anxiety have also been found among
adolescent samples. Biederman and colleagues (1991c) assessed a sample of clinicallyreferred patients aged 6-17 years using structural diagnostic interviews with parents.
Thirty percent of this sample met diagnostic criteria for ADHD and one or more
comorbid anxiety disorders (Biederman et al., 1991c). Another study compared the
prevalence of ADHD and comorbid psychopathology in preschool children and schoolaged youth and found similar degrees of ADHD and comorbid anxiety in both cohorts,
with prevalence rates around 30% (Wilens et al., 2002).
1.7.4 ADHD and Anxiety Disorders in Adults. An elevated prevalence of
anxiety disorders is also present in adult ADHD. In the National Comorbidity Survey
replication, Kessler and colleagues (2006) found a 47% prevalence rate of anxiety
disorders among adults with ADHD. Adults with ADHD also had significantly higher
odds of anxiety compared to the general population (OR = 3.7). Also, Biederman and
colleagues (1993) reported on a large sample of clinic-referred adults with ADHD
identified during a family study of children with ADHD, and a control group of adults
without ADHD obtained through the same study. The results indicated a high incidence
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of lifetime diagnoses of anxiety disorders (43% to 52%). Shekim and colleagues (1990)
examined 56 clinically-referred adults who met DSM-III-R criteria for ADHD (n = 56),
53% of whom also met criteria for generalized anxiety disorder (Shekim, 1990). A
clinical study conducted by Murphy and Barkley (1996) (n = 202) found the prevalence
of anxiety in adult ADHD to be approximately 32% (Murphy & Barkley, 1996).
Furthermore, the co-occurrence of ADHD and generalized anxiety appears to be robust,
also existing in international populations (Souza, Pinheiro, Denardin, Mattos, & Rohde,
2004).
The vast majority of prevalence estimates for concurrent ADHD and anxiety
disorders in children, adolescents, and adults are derived from clinically-referred samples
and studies examining the co-occurrence of these disorders using representative samples
of the general population are sparse. Therefore research on adult ADHD and concurrent
disorders in the context of the general population in Canada is necessary not only to
address the scarcity of population studies in the ADHD-anxiety literature, but also to
investigate adult ADHD and internalizing disorders in a Canadian context.
1.8 ADHD and Externalizing Disorders
1.8.1 ADHD, Oppositional Defiant Disorder and Conduct Disorder. Along
with ADHD, oppositional defiant disorder (ODD) and conduct disorder (CD) are the
most frequently studied psychiatric conditions of childhood (Althoff et al., 2003). The
defining feature of ODD is a persistent pattern of hostile and defiant behaviour towards
authority figures causing considerable impairment, whereas CD is described as a
continuous pattern of aggressive behaviour that consistently violates both the rights of
others and age-appropriate social norms (APA,1994). The prevalence of ODD ranges
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from 2-15% and the prevalence of CD ranges from 1.5-3.4%, with some estimates as
high as 16% contingent upon the type of sample under study (Althoff et al., 2003). Also,
there is a higher prevalence of ODD and CD among boys than girls.
ADHD frequently co-occurs with ODD (35%) and CD (50%) (Althoff et al.,
2003). Comorbid disruptive disorders are so pervasive that may not be separable, with
some authors suggesting that ADHD subtypes with ODD and CD should be considered
(Jensen, Martin & Cantwell, 1997). Conversely, evidence also exists suggesting that
ODD and CD are distinct disorders from each other and from ADHD (Loeber, Burke,
Lahey, Winters & Zera, 2000).
Although the disruptive disorders (ADHD, ODD and CD) are among those most
commonly seen by pediatricians, family practitioners, psychologists, and psychiatrists,
they often remain underdiagnosed, misdiagnosed or untreated (Althoff et al., 2003). The
paucity of treatment of these disorders is concerning, since ODD and CD have been
found to be associated with negative psychosocial outcomes such as substance abuse and
criminality (Robins & Price, 1991; Walters & Knight, 2010). CD has been found to be a
strong predictor of antisocial personality disorder (ASPD) in adulthood (Robins & Price,
1991) as several studies of clinic and population-based samples have shown that
childhood conduct problems predict serious adult antisocial behaviour (Hill, 2003;
Kratzer & Hodgins, 1997; Robins, 1978).
1.8.2 ADHD and Antisocial Personality Disorder. Antisocial personality
disorder (ASPD) is a term used to designate a pattern of behaviours which include the
failure to conform to social norms and the law, a reckless disregard for the safety of
others and consistent irresponsibility among those 18 years or older (APA, 1994). A
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diagnosis of antisocial personality also warrants the diagnosis of its childhood precursor
conduct disorder (APA, 1994). ADHD has been found to be significantly associated with
ASPD in adulthood, as longitudinal studies of ADHD children have revealed high rates
of ASPD in later life (Barkley, Fischer, Smallish, & Fletcher, 2004; Mannuzza, Klein,
Bessler, Malloy, & LaPadula, 1998; Satterfield & Schell, 1997; Weiss, Hechtman, Milroy
& Perlman, 1985). In their 15-year prospective follow-up study of 61 hyperactive boys
and 41 controls, Weiss and colleagues (1985) found that the only DSM-III diagnosis that
was significantly more prevalent in the probands than the comparison subjects was ASPD
(23% versus 2%) (χ2 = 8.22, df = 1, p < .01). Another prospective follow-up study of
clinically-referred boys (n = 104) showed that approximately 20% of children with
ADHD enter adulthood with ASPD (Manuzza et al., 1998). In an earlier study by the
same authors, 27% of the probands and only 8% of the comparison subjects had ongoing
ASPD (χ2 = 12.50, df = 1, p < .0001) (Manuzza et al., 1993). These findings were also
replicated in yet another study conducted by the same authors with an independent cohort
of 104 boys. Here, 32% of the probands and 8% of the comparison subjects had ongoing
ASPD (χ2 = 15.11, df = 1, p < .0001) (Manuzza et al., 1991). These studies provide
evidence for an association between ADHD in childhood and ASPD in adulthood.
Magnetic resonance imaging (MRI) studies of the brains of persons with ASPD
suggest that these individuals also exhibit frontal cortical deficits (Raine, Lencz, Bihrle,
LaCasse & Colletti, 2000). Studies using both positron emission tomography (PET)
(Goyer et al., 1994; Volkow et al., 1995; Raine, Meloy, Bihrle, Stoddard, Lacasse &
Buchsbaumm, 1998) and single-photon emission computed tomography (SPECT)
(Amen, Stubblefield, Carmicheal & Thisted, 1996; Kuruoglu, Arikan, Vural, Karatas,
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Arac & Isik, 1996) have shown that poor prefrontal processing is exhibited in violent,
antisocial persons, a deficit that is also a cardinal feature of ADHD. Therefore, similar
abnormalities in areas that are critical in modulating emotion, arousal, and attention are
characteristic of both ADHD and ASPD.
In addition to common neural deficits, both ADHD and ASPD individuals are low
on the personality trait known as effortful control (Frick & Morris, 2004; Nigg, 2006).
Effortful control refers to the ability to focus attention resources and to inhibit
behavioural responses and is critical to emotion regulation (Frick & Morris, 2004). There
is robust evidence that a temperamental vulnerability termed ‘low effortful control’ is a
risk factor for the development of oppositional/noncompliant antisocial behaviour (Frick
& Morris, 2004; Nigg, 2006).
ADHD has been shown to increase the risk for ODD and CD, thus consequently
increasing the risk for the development of antisocial behaviour, as explained by
developmental pathway theories that argue that antisocial behaviour evolves in a largely
predictable manner (Frick & Marsee, 2006; Loeber, Green, & Lahey, 2003;Waschbusch,
2002). Therefore, it is not surprising that ASPD has been found to be significantly
associated with ADHD due to corresponding features present in both disorders.
1.9 ADHD and Substance Use Disorders
Substance use refers to the ingestion of drugs of abuse, inhalants, or medications
for the purpose of intoxication (APA, 1994). As outlined in the DSM-IV, the substance
use disorders (SUDs) are divided into substance abuse disorder and substance
dependence disorder. The necessary feature of substance abuse disorder is a recurrent
pattern of substance use despite negative consequences related to the use of the substance
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(APA, 1994). An example of substance abuse would be binging on alcohol or drugs.
Substance dependence disorder on the other hand, is a collection of cognitive,
behavioural and physiological symptoms demonstrating that the individual continues
substance use despite substance-related problems including the development of tolerance
and withdrawal symptoms, hence being ‘dependent’ on a particular substance or
substances (APA, 1994). Of the SUDs, substance dependence disorder is more severe
than substance abuse disorder.
Concurrent SUDs are of particular concern in the treatment of ADHD because
habit-forming stimulant medication is currently the gold standard in treatment of the
disorder. Given the need to identify antecedent risk factors to initiate early intervention in
SUD, in addition to the clinical implications of concurrent ADHD and SUD, several
authors have investigated the relationship between ADHD and SUD and have even
proposed ADHD as a possible causal mechanism for the development of subsequent
SUD.
In their meta-analysis of longitudinal studies that prospectively followed children
with and without ADHD, Lee, Humphreys, Flory, Lui and Glass (2011) found that
children with ADHD were significantly more likely to have ever used drugs, but not
alcohol. In addition, children with ADHD are also more likely to develop disorders of
abuse/dependence for alcohol, marijuana, cocaine, and other substances (i.e., unspecified)
(Lee et al., 2011). The authors’ concluded that individuals with ADHD are significantly
more likely to develop SUDs than those without ADHD and that this increased risk was
evident despite demographic and methodological differences that varied across studies.
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The relation between ADHD and SUDs is bidirectional in nature in that the
prevalence of ADHD is approximately 1-5% in the general adult population, yet it affects
between 11 and 35% of adults with SUD (Kalbag & Levin, 2005) and between 25 and
50% of adolescents with SUD (Wilens & Biederman, 2006). Furthermore, several studies
involving adults with alcohol and drug use disorders show that from 15 to 25% referred
for SUD also have ADHD (Carroll & Rounsaville, 1993; Levin, Evans & Kleber, 1998;
Schubiner et al., 2000; Wilens, 2004a).
A sex difference in ADHD and the risk for SUDs has also been documented.
Research using both community and clinical samples suggests that compared to boys,
ADHD girls have a higher risk for substance use by early adolescence (Biederman et al.,
1999; Disney, Elkins, McGue & Iacono, 1999). For example, as part of the Minnesota
Twin project, Disney and colleagues (1999) reported trends towards higher rates of SUD
within the past month in 17 year old ADHD girls compared to ADHD boys of the same
age (any substance use: 73% versus 44%; SUD: 29% versus 14%, respectively).
Similarly, studies by Biederman and colleagues (1991, 1999) demonstrate a greater agecorrected risk for SUD in ADHD girls relative to boys. As such, ADHD girls appear to be
at greater risk for SUD than ADHD boys, yet ADHD alone nonetheless acts as a risk
factor for SUD regardless of gender.
Studies suggest that compared to their non-ADHD peers, ADHD individuals
appear to preferentially use drugs instead of alcohol (Biederman et al., 1995; Biederman
et al., 1997; Molina & Pelham, 2003). However, the choice of a specific drug of abuse
(e.g. cocaine over marijuana) or drug type (stimulant or depressant) has not been shown
for persons with ADHD and concurrent SUD (Biederman et al., 1995; Biederman et al.,
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1997). Pharmacological treatment of ADHD has been found to attenuate the risk of
subsequent SUD in some studies. For instance, a meta-analysis of the literature revealed
that ADHD youth who were treated with stimulant medication had twice the reduction in
risk for SUD compared to those not receiving pharmacotherapy for ADHD (Wilens et al.,
2003). However, other studies have found no evidence that stimulant medication
increases or decreases risk for subsequent SUD (Biederman, Monuteaux, Spence, Wilens,
MacPherson & Faraone, 2008). Regardless of the various reasons for use, adult ADHD
has an especially negative impact on the development and course of SUD. Individuals
with ADHD have been found to show an earlier onset of SUD, a more rapid progression
of SUD, a greater severity of SUD, and a prolonged course of SUD (Wilens & Morrison,
2011).
As shown in the above literature review, studies of the prevalence of ADHD and
concurrent disorders show a substantial variability in estimates. This, in part, may be due
to an inconsistency of measures used to ascertain these estimates. In addition, the
selection of cut points to determine the presence or absence of a given disorder may
differ, resulting in variable figures. Moreover, some studies employed measures whose
psychometric properties were wanting.
The observed variability in the prevalence of ADHD and concurrent disorders can
be attributed to the clinical nature of the samples. Specifically, ADHD studies are largely
based on clinical pediatric samples exhibiting significant gender discrepancies resulting
in biased results that cannot be generalized to populations that do not conform to the
specified characteristics of these samples. Furthermore, most ADHD studies to date have
been conducted in the United States and therefore, may not be comparable to Canadian
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findings. There is a marked deficit of Canadian epidemiological evidence regarding
ADHD mental health correlates. As such, studies using population-based data from
Canadian adults are necessary not only to address age differences, but also referral bias
concerns and gender bias in order to better describe ADHD prevalence, mental health
correlates and substance use in Canada.
1.10 Study Objectives
The current study used population-based data from Ontario adults to 1) estimate
the prevalence of adult ADHD (using an ADHD screener), previous diagnosis and
stimulant medication use correlated mental health issues and substance use in Ontario; 2)
examine the sex differences in the prevalence of ADHD screener status, psychiatric
distress and substance use in ADHD and 3) model ADHD screener status as a risk factor
for psychiatric distress. The above aims were achieved using data gathered from the 2011
cycle of the Centre for Addiction and Mental Health (CAMH) Monitor, a cross sectional
telephone survey of Ontarians 18 years of age and older.
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Chapter 2: Methods
2.1 Study Design
This study was a secondary data analysis conducted using cross-sectional data
from the Centre for Addiction and Mental Health (CAMH) Monitor, a large ongoing
population-based survey of Ontario adults aged 18 and over collected in 2010-2011
(Ialomiteanu & Adlaf, 2012).
2.2 CAMH Monitor
2.2.1 Survey Design. Data were collected using the CAMH Monitor, an ongoing
cross-sectional telephone survey of Ontario adults aged 18 and over. The survey was
designed to monitor addictions and mental health issues in Ontario, including alcohol and
drug consumption, public opinion on these topics, and mental health status. The 2011
CAMH Monitor was an aggregation of 12 independent monthly surveys (January to
December).
2.2.2 Sampling Strategy. The target population of the current study was noninstitutionalized adults 18 years of age and older residing in Ontario households during
the year 2011. The sampling frame was based on adult telephone subscribers residing in
Ontario who were capable of completing the interview in English. Participants were
contacted via random-digit dialing and were selected from a sampling frame of all active
area codes and exchanges in Ontario provided each month by the American Telephone
and Telegraph (ATT) Long Lines Tape.
Since 2000, the CAMH Monitor sampling frame has consisted of listed 10-digit
telephone numbers in Ontario. The numbers that are listed and selected, along with
telephone numbers between or on either side of that number, are included in the sampling
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frame. For example, if the selected number 416-651-8513 is published in a directory, then
all numbers from 416-651-8510 to 416-651-8519 are included in the sampling frame
even if they are cell phone numbers or unlisted numbers. Numbers are only excluded if
they are identified “not-in-service” numbers. A computer is then used to generate a
random sample of telephone numbers from this frame from which each quarterly sample
is drawn. Because unlisted numbers, cell phone numbers, and newly published numbers
are interspersed among published numbers in the sampling frame, this strategy provides a
much more robust sample than one restricted to listed landline numbers alone
(Ialomiteanu & Adlaf, 2012). Moreover, studies using exclusively landlines have been
shown to underestimate several health behaviours such as binge drinking and smoking
(Blumberg, Luke, & Cynamon, 2006).
The sampling design employed a stratified two-stage probability selection
procedure occurring each quarter. For the purpose of this survey, the province is divided
into six geographical regions: Toronto, Central West, Central East, West, East, and
North. In the first stage of selection, a random sample of telephone numbers was selected
from within each of the six regional strata. In stage two, one respondent aged 18 or older
who was able to complete the interview in English was selected without replacement
based on the most recent birthday of all household members (Ialomiteanu & Adlaf,
2012). According to O’Rourke and Blair (1983), the most recent birthday technique is a
relatively non-intrusive method for producing an unbiased sample. Unanswered numbers
were called back a minimum of 12 times and households that initially refused to
participate were re-contacted to ensure maximum participation (Ialomiteanu & Adlaf,
2012).
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Two-stage probability sampling differs in subtle ways from simple random
sampling (SRS). The selection of respondents from household by most recent birthday
creates a design effect (DEFF). Design effects are the ways departures of the sampling
frame from simple random sampling impact statistical estimates from the sample. The
DEFF is basically the ratio of the actual variance under the sampling method used, to the
variance computed under the assumption of simple random sampling (Henry, 1990). The
implication of using SRS formulas on estimates from complex sampling designs is the
underestimation of the error and the construction of narrower confidence intervals than
truly exist, resulting in false positive findings of statistical significance (Henry, 1990). As
such, a greater number of type I errors (false positive statistically significant differences)
are more likely.
A DEFF of 1.0 indicates that the variance of a given sample design is equivalent
to the variance of a SRS and most complex survey designs tend to have DEFFs larger
than one (Ialomiteanu & Adlaf, 2012). However, random-digit dialing telephone surveys
typically have smaller DEFFs relative to multistage, clustered area samples (Ialomiteanu
& Adlaf, 2012). DEFFs in the current study ranged from 1 to 2 (Ialomiteanu & Adlaf,
2012). Therefore, most of the statistically significant differences generated from standard
statistical software would be correct, yet some may not be, especially those involving
small sample sizes.
2.3 Study Population, Inclusion Criteria and Exclusion Criteria
The current study included respondents from the 2011 cycle of the CAMH
Monitor (n = 3039). This cycle was the first to include questions regarding adult ADHD,
previous ADHD diagnosis, and previous ADHD medication use. Furthermore, the 2011
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cycle was also the first cycle to include questions on antisocial personality disorder.
Excluded by design are Ontario households that are phoneless, which represent 1% of
Ontario residents (Statistics Canada, 2011). Also excluded are those too ill or aged to be
interviewed and those unable to communicate on the telephone or in English. Therefore,
the CAMH Monitor is representative of non-institutionalized English-speaking Ontarians
age 18 and older who are sufficiently healthy to answer a telephone (n = 9,118,084 from
2001 Ontario Census) (Ialomiteanu & Adlaf, 2012).
2.4 Data Collection
Data were collected from January 3rd through December 20th 2011. All interviews
were conducted by trained staff from the Institute for Social Research (ISR) at York
University. On average, the 2011 interviews lasted 23 minutes (range 6-71 minutes;
median 22 minutes) with 90% of interviews completed within 30 minutes (Ialomiteanu &
Adlaf, 2012). The interviews used computer-assisted telephone interviewing (CATI)
which consists of telephone, video monitor and computer keyboard to ask questions and
record participants’ responses (Bondy, 1994). The computer program associated with the
questionnaire controlled the presentation of items on the video monitor during the
interview. The CATI system followed a programmed skip pattern and customized the
wording of some items to make the interview flow smoothly and ensure consistency
between interviewers. Interviews were conducted by 60 ISR interviewers, many of whom
had considerable CATI experience and had completed interviews on prior CAMH
surveys (Ialomiteanu & Adlaf, 2012).
CATI technology allowed for the blind supervision of interviewers while
simultaneously storing participant responses in computer data files. CATI systems are
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preferred over the more traditional paper and pencil questionnaires as they produce fewer
errors and missing data (Cattlin & Ingram, 1988). One advantage of the CATI system
over paper and pencil questionnaires is that the computer program notifies the interviewer
of out of range values and interviews cannot proceed until the value error is rectified.
A matrix interview design was used in order to reduce respondent burden and
maximize questionnaire content and flexibility. Here, random subsets of respondents
within each panel are asked one set of questions, whereas other subsets of respondents
are asked a different set of questions. The majority of the interview consists of core items
which were asked of all respondents. Two interview schedules were employed for the
remaining questions on the survey. Panel A represents interviews with 1,040 respondents,
and Panel B represents interviews with 1,999 respondents. Only panel B was analyzed in
this study as it comprised all questions pertaining to ADHD.
2.5 Response Rates
Of the 8,277 telephone numbers selected over the four quarters of 2011, 5,677
were estimated to be eligible and 3,039 respondents participated, representing an
effective response rate of 51% (quarterly response rates varied from 50% to 52%). This
response rate was lower than previous years (57% in 2009, 55% in 2008, 53% in 2007,
and 60% in 2006) (Ialomiteanu & Adlaf, 2010). Unit response rates for the 20 surveys
conducted between 1991 and 2010 were found to vary from 51% to 69% with an average
of 62% (Ialomiteanu & Adlaf, 2010).
These response rates are similar to those achieved by other high quality surveys in
the past decade. For example, the Canadian Alcohol and Drug Use Monitoring Survey,
conducted in 2010, obtained an overall response rate of 44% (Health Canada, 2010).
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Also, the Behavioural Risk Factor Surveillance System, the largest health risk survey
conducted in the United States by the Centers for Disease Control and Prevention,
obtained an overall response rate of 41% in 2004 (Centers for Disease Control and
Prevention, 2004). Further, the University of Michigan’s Survey of Consumer Attitudes
found a decline in response rates from 60% in 1996 to 48% in 2003 (Curtin, Presser, &
Singer, 2005).
2.6 Survey Instrument
The CAMH Monitor was written for use with the CATI interviewing system. The
corresponding telephone interview averages 25 minutes in duration (Ialomiteanu &
Adlaf, 2010). There are over 300 items, but no respondents were administered all items
due to panel divisions and logical skip patterns designed into the survey. For example, if
a respondent was asked if they consumed any alcoholic beverages in the past year and
responded no, any questions regarding alcohol consumption in the last seven days would
be skipped.
2.7 Measures
2.7.1 Adult ADHD Self-Report Scale (ASRS-v1.1). Developed by the World
Health Organization, the Adult ADHD Self-Report Scale (ASRS- v1.1) Screener is a sixitem checklist used to assess ADHD symptoms based on DSM-IV criteria for ADHD. The
ASRS-v1.1 Screener was designed to effectively capture the three primary symptom
domains of ADHD: hyperactivity, impulsivity and inattention. The ASRS-v1.1 Screener
questions were selected using stepwise logistic regression analysis. This method selects
the least redundant set of symptoms in an effort to maximize prediction of an external
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criterion, in this case, the DSM-IV diagnosis of ADHD (Kessler, Adler, Gruber, Sarawate,
Spencer & Van Brunt, 2007).
The wording of questions in the ASRS-v1.1 Screener differs slightly from the
wording in other ADHD rating scales. Unlike the items in previous ADHD scales, the
questions in the ASRS-v1.1 Screener are designed to suit adult, rather than child
respondents. The language in the ASRS also provides a context for symptoms to which
adults can relate, to better capture adult ADHD symptom manifestations. To this end,
references to such things as play and schoolwork were deleted. Therefore by using
language and context specific to adults, the ASRS-v1.1 Screener addresses the issue of
variability in ADHD symptom expression between children and adults, which was a
concern raised by Biederman et al. (2000) and Faraone et al. (2000) in regards to other
ADHD scales.
The ASRS-v1.1 Screener measures the frequency of ADHD symptoms. The
developers of the instrument employed frequency-based ratings in order to allow
respondents to focus on symptom occurrence, rather than on symptom severity. The
ASRS-v1.1 Screener has an expanded rating scale of zero to four, which allows more
accurate discrimination of symptom frequency. For example, the previously combined
‘never or rarely’ response option from other ADHD rating scales, was separated into: 0
‘never’, 1 ‘rarely’, 2 ‘sometimes’, 3 ‘often’, and 4 ‘very often’ on the ASRS Screener.
The optimal scoring approach for the ASRS-v1.1 Screener involves summing the items’
numeric response options (0-4). This method yields a summary score with a theoretical
range of 0-24 (as opposed to the 0-6 scoring approach which was found to be less
discriminative) (Kessler et al., 2007).
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Using the 0-24 scoring approach with a cutoff score of 14, the ASRS-v1.1
Screener demonstrated high concurrent validity, as the Screener was found to have a
strong concordance with clinician diagnosis with an area under the receiver operating
characteristic curve (AUC) of 0.90 (Kessler et al., 2007). The ASRS-v1.1 Screener has a
sensitivity of 0.65 (SE = 0.23), specificity of 0.94 (SE = 0.3), a positive predictive value
(PPV) of .50, and a negative predictive value (NPV) of .97 (Kessler et al., 2007). Overall,
the ASRS-v1.1 Screener had a total classification accuracy of 0.92 (SE = 0.38) (Kessler
et al., 2007). These findings show that the ASRS-v1.1 is better at ruling in adult ADHD
than ruling it out. However, a more recent study by Hines and colleagues (2012)
compared the ASRS-v1.1 Screener and the Conner’s Adult ADHD Self Report Scale Self
Report-Short Version (CAARS-S: S) in a primary care setting. These authors found that
the ASRS showed a sensitivity of1.0, a specificity of 0.71, a PPV of 0.52, and a NPV of
1.0 (Hines, King & Curry, 2012). The high sensitivity suggests that cases of adult ADHD
are rarely missed by the ASRS-v1.1. Furthermore, the moderately high specificity and
NPV of 0.99 suggest that the ASRS-v1.1 Screener does not identify someone as having
adult ADHD in they in fact do not. Therefore, these values show that the ASRSv1.1Screener would rarely miss someone with adult ADHD and would also be successful
at discounting non-cases.
In order to assess the test-retest reliability of the ASRS-v1.1 Screener, Kessler and
colleagues (2007) administered the Screener at baseline, again six months to one year
after initial screening, and once more one to three months after the second screening.
This allowed the authors to calculate the correlations between times one, two and three.
The ASRS-v1.1 Screener was found to have test-retest reliabilities ranging from .58- .77
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(Kessler et al., 2007). The ASRS-v1.1 Screener was found to have internal consistency
reliabilities (Cronbach’s alphas) ranging from .63- .72, demonstrating acceptable
intercorrelations between items on the Screener (Kessler et al., 2007). The authors note
however that very high Cronbach’s alphas would not be expected because the ASRS
Screener questions were selected by stepwise logistic regression analysis, a method
which optimizes inconsistency among items in a way that would be reflected in low
estimates of internal consistency (Kessler et al., 2007). In addition to its applicability in
assessing adult ADHD, the sound psychometric properties of the six-question ASRS-v1.1
Screener make it a useful screening tool for epidemiological research.
Variables adh1-adh6 represented the six ASRS Screener items. The ASRS
Screener items are presented in Appendix A.
Response options to variables adh1 to adh6 were 1 ‘never’, 2 ‘rarely’, 3
‘sometimes’, 4 ‘often’ and 5 ‘very often’ in the Monitor. These variables were recoded to
correspond to the Kessler and colleagues (2007) response options, 0 ‘never’, 1 ‘rarely’, 2
‘sometimes’, 3 ‘often’, and 4 ‘very often’ mentioned above. Reponses to each question
were then summed, yielding summary scores with a theoretical range of 0-24. A derived
variable delineating positive from negative ADHD screens was created using a summary
score threshold of 13/14, as it corresponds to the optimal cutoff score for case-finding
using the 0-24 scoring approach recommended by Kessler and colleagues (2007).
Kessler and colleagues (2007) also recommended that the 0-24 summary scores
be classified according to four strata denoting high negative to high positive Screener
scores. A derived variable was created with four values: 1 ‘high negative, 2 ‘low
negative, 3 ‘low positive and 4 ‘high positive’ (strata). The high negative stratum
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represented participants with ASRS Screener scores 0-9; the low negative, scores 10-13;
the low positive, scores 14-17; and the high positive, scores greater than or equal to18.
2.7.2 Previous ADHD diagnosis and medication use. Previous ADHD diagnosis
was assessed by the item ‘have you ever been diagnosed with Attention Deficit Disorder
(ADD) or Attention Deficit Hyperactivity Disorder (ADHD) by a doctor or health care
professional?’ (adh11).
Drawn from the Ontario Student Drug Use and Health Survey (Paglia-Boak et al.,
2012), the item ‘have you ever been treated with MEDICATION for ADHD or ADD by a
doctor or health care professional?’ (adh12) assessed previous ADHD medication use.
2.7.3. General Health Questionnaire (GHQ-12). The GHQ-12 is a self-report
screening instrument that measures current mental health status while focusing on two
areas: the inability to execute normal ‘healthy’ functions and the appearance of novel and
distressing experiences. The questionnaire asks respondents about their recent experience
of particular psychological symptoms and probes whether these symptoms are worse than
usual. The GHQ-12 is intended for adults 16 and over and consists of 12 questions
balanced in agreement sets. That is, half of the items are worded positively and the other
half is worded negatively. Responses are categorized along a four point Likert scale with
response options 0 ‘not at all’, 1 ‘no more than usual’, 2 ‘rather more than usual’, and 3
‘much more than usual’. Items gq1 through gq12 in the CAMH Monitor correspond to
the GHQ-12 items.
Lewis and Wessely (1990) found that the convergent validity between the GHQ-12
and the Hospital Anxiety and Depression Scale was 0.74. Furthermore, Goldberg and
colleagues (1997) studied the validity of the GHQ-12 in 15 countries and found no
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significant differences in the validity of results by age, sex and education or between
developed and developing countries.
In a comprehensive review of the GHQ-12, Vieweg and Hedlund (1983) found
that Cronbach’s alpha coefficients ranged from .82 to .90 (Vieweg & Hedlund, 1983;
Goldberg et al., 1997). Clinical assessments of psychiatric illness have been found to be
directly proportional to the number of symptoms reported on the GHQ-12, demonstrating
good external consistency (Goldberg & Huxley, 1980). The median sensitivity and
specificity drawn from 17 studies was 83.7% and 79.0% respectively (Goldberg et al.,
1997).
There are three scoring approaches for the GHQ-12, a binary method (ex. 0-0-11), a Likert method (ex. 0-1-2-3) and the C-GHQ method. The standard method of
scoring the GHQ is the binary method where symptomatic responses to each item are
scored ‘1’ and summed over the items, resulting in a score ranging from 0-12 (Goldberg
et al., 1997). The Likert scoring method involves assigning response scores of 0-3 to each
item. These scores are then summed across items, giving an overall score ranging from 0
to 36 (Goldberg et al., 1997). Another scoring method, the C-GHQ method, scores
positive items in the binary method and negative items are scored 0-1-1-1, thus assuming
that the ‘no more than usual’ response to negative questions indicates the presence of a
chronic problem rather than good health (Goldberg et al., 1997). In all three scoring
methods, higher scores indicate an increased likelihood of psychiatric distress.
Goldberg and colleagues (1997) found that the Likert and C-GHQ scoring
methods offer no advantage over the simpler binary scoring method for the GHQ-12. The
same study found 1/2 to be the optimal threshold with an ROC of 0.88, 83.5% sensitivity
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and 75.1% specificity (Goldberg et al., 1997). However, in their study using the CAMH
Monitor to determine optimal GHQ-12 threshold values for the Ontario population, Mann
and colleagues (2011) identified 4 as the value at which both sensitivity and specificity
are maximized. This cut-off provided estimates of prevalence of probable anxiety and
mood disorder (psychiatric distress) in the Ontario population nearly identical to those
found in the Canadian adult population with the CIDI (Rush et al., 2008).
Therefore, after summing GHQ-12 responses using the binary scoring method, a
cut-off score of 4 was used to delineate cases of psychiatric distress from non-cases.
2.7.4 Psychotropic medication use. Two items addressed psychotropic
medication use. One item corresponded to antidepressant medication use, ‘in the past 12
months have you taken any prescription medication to treat depression?’(ps11) and the
other to anxiolytic medication use, ‘in the past 12 months have you taken any
prescription medication to reduce anxiety or panic attacks?’ (ps16). Both items had
binary response options ‘yes’ and ‘no’.
2.7.5 The Antisocial Personality Disorder Scale from the Mini-International
Neuropsychiatric Interview (MINI-APD). The Mini-International Neuropsychiatric
Interview (MINI) is a screening tool used to identify individuals in need of further mental
health assessment (Sheehan et al., 1998). The MINI consists of a structured diagnostic
interview comprised of 120 questions, and assesses the presence of the 19 most common
DSM-IV and International Statistical Classification of Diseases and Related Health
Problems, 10th Revision (ICD-10) disorders, 17 Axis I disorders, one Axis II disorder
(antisocial personality disorder) and suicidal ideation/attempts. Items are answered
dichotomously as either ‘yes’ or ‘no’.
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The current study was concerned solely with the antisocial personality disorder
module from the MINI. The MINI-APD module consists of 12 behavioural questions
largely drawn directly from the diagnostic criteria for ASPD and from the diagnostic
criteria for conduct disorder prior to age 15 (a necessary requirement for diagnosis of
ASPD). The ASPD section involves two areas of interest. In the first section, subjects are
asked about six specific problematic childhood misbehaviours; if two or more questions
are endorsed, subjects are subsequently asked about six antisocial behaviours since age
15. Three or more of these behaviours are required for a diagnosis of ASPD.
The MINI was found to have acceptably high validity, inter-rater and test-retest
reliability scores for most disorders when compared with both the Structured Clinical
Interview for DSM-III-R (SCID) and the CIDI (Pinninti, Madison, Musser & Rissmiller,
2003; Lecrubier, Sheehan, Hergueta, & Weiller, 1997; Sheehan et al., 1997). Sheehan
and colleagues (1998) found kappas over 0.70 for most of the psychiatric diagnoses and
only a single kappa value (current drug dependence) being under 0.50. Sensitivity was
0.70 for all disorders except dysthymia, obsessive-compulsive disorder, and current drug
dependence. PPVs were above .75 for major depression, lifetime mania, current and/or
lifetime panic disorder, lifetime agoraphobia, lifetime psychotic disorder, anorexia, and
posttraumatic stress disorder. However, none of these studies assessed the antisocial
personality disorder module of the MINI. As such, information regarding the validity and
reliability of the ASPD module is lacking.
For the present study, the MINI-APD module was shortened by one item to 11
items in total. The first section consists of only 5 items instead of 6 (items apd1 through
apd5). For ethical reasons, item six from the MINI ASPD module, ‘before you were 15
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years old did you force someone to have sex with you?’ was excluded from the CAMH
Monitor and therefore from the current study. Scoring the first five items was
programmed directly into the CATI interviewing system and differed from the
aforementioned scoring. In order to be asked the next set of ASPD questions, participants
must have endorsed greater than three questions out of the initial five (instead of two out
of six). Similar to the original scoring developed by Sheehan and colleagues (1998),
antisocial personality disorder was identified as present if a participant scored three or
higher on the latter six questions (apd6 through apd11). A dichotomous variable
delineating those who screened positive from those who screened negative for ASPD was
created using a scoring threshold of 5/6.
2.7.6 Alcohol Use Disorders Identification Test (AUDIT).
The Alcohol Use Disorders Identifications Test (AUDIT) was developed by the
World Health Organization, Department of Mental Health and Substance Dependence to
identify the presence or absence of an alcohol use disorder. The AUDIT contains 10
items and 4 subscales and takes about two minutes to administer (Babor, Biddle-Higgins,
Saunders & Monteiro, 2001). Response options range from zero to four, however the
phrases associated with the numeric response options vary depending on the item. A
score of eight or more denotes hazardous alcohol use (Babor, Biddle-Higgins, Saunders
& Monteiro, 2001).
The AUDIT has demonstrated a high degree of internal consistency across a
broad range of studies. In their review of studies prior to the year 2001, Shields and
Caruso (2003) calculated a median reliability of .81, with a range of .59 to .91. In a
review of 18 studies published since 2002, Reinert and Allan (2007) found a comparable
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median reliability coefficient of .83, with a range of .75 to .97. Using the standard cutpoint of eight, three studies were conducted with general population samples and reported
test-retest reliability kappas of .70, .86, and .89 respectively (Dybek, Bischof, Grothues,
Reinhardt, Meyer, Hapke, et al., 2006; Rubin, Migneault, Marks, Goldstein, Ludena &
Friedman, 2006; Selin, 2003).
Interclass correlations have also confirmed the stability of the test-retest reliability
of the AUDIT in general population samples. Rubin and colleagues (2006) derived an
interclass correlation coefficient of .87 among 102 participants from the general U.S.
population who were screened by telephone with a seven day interval between
screenings. In their study of 61 participants from the general Swedish population,
Bergman and Kallmen (2002) reported an interclass correlation of .93 between initial
screening and three to four week follow-up. Moreover, Dybek and colleagues (2006)
screened 99 German general practice patients and found an interclass correlation of .95
between the initial in-person screening and a one month follow-up by telephone. The
AUDIT has therefore repeatedly been shown to have good test-retest reliability.
Regarding the construct validity of the AUDIT, the stability of a two factor
structure has been demonstrated across numerous studies. These studies support a
‘consumption’ factor (items one to three) and an ‘adverse consequences of drinking’
factor (items four to ten). Bergman and Kallmen (2002) found a Cronbach’s alpha
reliability coefficient of .69 and a test–retest reliability of .98 for the consumption factor
items. Shields, Guttmannova and Caruso (2004) found Cronbach’s alphas of .74 and .81
for the scores on the same consumption factor in a clinical and a college student sample.
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Measures of the criterion validity of the AUDIT have varied across studies.
Studies examining the concurrent and the predictive validity of the AUDIT using the
DSM-IV criteria for alcohol abuse or dependence reported that the sensitivity of the
AUDIT ranged from .67 to 1.00 and the specificity from .65 to .97 (Cherpitel, 1997;
Cherpitel, 1998; Cherpitel, 2001; Clements, 1998; Cook, Chung, Kelly & Clark, 2005;
Dawe, Seinen & Kavanagh, 2000; Hearne, Connolly & Sheehan, 2002; Kelly, Donovan,
Chung, Cook & Delbridge, 2004; Maisto, Carey, Carey, Bordon & Gleason, 2000;
McCann, Simpson, Ries & Roy-Byrne, 2000). These same studies reported positive
predictive values (PPVs) and negative predictive values (NPVs) ranging from .32 to .87
and .88 to .98 respectively.
The AUDIT is scored as follows. The first response for each question (e.g.
‘never’) is scored zero. The second response option (e.g. ‘less than monthly’) is scored
one, the third (e.g. ‘monthly’) is scored two, the fourth (e.g. ‘weekly’) is scored three and
the last response (e.g. ‘daily or almost daily’) is scored four. Questions nine (aud9t) and
10 (aud10t) have three response options and these are scored zero, two, and four
respectively. Scores are then summed to obtain a total score ranging from 0-40 (audit). A
total score of eight or more denotes hazardous alcohol use. The variable audit8 delineates
those who screened positive for hazardous alcohol use from those who screened negative
for hazardous alcohol use.
2.7.7 Alcohol, Smoking and Substance Involvement Screening Test (ASSIST).
The Alcohol and Substance Involvement Screening Test (ASSIST) was developed for the
World Health Organization by an international collaborative of substance abuse
researchers to screen primary care patients for psychoactive substance use and related
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problems (WHO ASSIST Working Group, 2002). The ASSIST is a self-report measure
consisting of eight questions, the first of which asks the respondent about any lifetime use
of tobacco, alcohol, cannabis, cocaine, stimulants, inhalants, sedatives/hypnotics,
hallucinogens, opioids and ‘other drugs’. If the respondent answers no, the screen is
complete. If the respondent answers yes however, the next seven items are administered.
These items probe areas such as health, social, financial or legal problems, inability to
manage routine responsibilities, expression of concern by friends or family, prior
attempts to control use associated with each drug that was positively endorsed in the first
question. The final question asks about intravenous drug use. Questions are rated on a
five-point Likert scale. The ASSIST takes less than five minutes to administer and is
designed to ascertain both lifetime and current substance use (WHO ASSIST Working
Group, 2002).
In their study examining the feasibility and reliability of the ASSIST with a group
of 236 participants, the WHO ASSIST Working Group (2002) found test-retest reliability
coefficients ranging from .58 to .90 with retest interviews occurring one to three days
after the initial screening. In general, reliabilities showed substantial agreement. The
same study evaluated the internal consistency reliability of the ASSIST and found that
the correlations were high for most items across all substance classes with Cronbach’s
alphas ranging from .73 to .92 (WHO ASSIST Working Group, 2002).
The concurrent, construct and discriminative validity of the ASSIST was
examined in a multi-site international study consisting of 1047 participants (Humeniuk et
al., 2008). This study utilized a stratified sampling procedure to ensure balanced
recruitment in regards to sex and age groups (18-25) (26-35) and (36-45) years
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(Humeniuk et al., 2008). Concurrent validity of the ASSIST was assessed by comparison
of scores with the Addiction Severity Index-Lite (ASI-Lite), the MINI-plus, the Severity
of Dependence Scale (SDS), the Revised Fagerstrom Tolerance Questionnaire (RTQ) and
the AUDIT. The authors found significant positive correlations between the ASSIST and
the ASI-Lite (r = .76- .88; p < .001), the MINI-Plus (r = .76, p < .001), the SDS (r = .59,
p = .001), the RTQ (r = .78, p < .001) and the AUDIT (r = .82, p < .001) (Humeniuk et
al., 2008) demonstrating the concurrent validity of this instrument.
The ASSIST also showed good internal consistency with Cronbach’s alpha
calculations displaying good inter-item correlations for the total substance involvement
score (.89) as well as for the specific substance involvement scores (.86 for cannabis)
(Humeniuk et al., 2008). Cannabis abuse and dependence thresholds were taken from the
Technical Report of Phase II Findings of the WHO ASSIST Project (Humeniuk & Ali,
2006). The authors investigated the discriminative validity of the ASSIST by comparing
ASSIST scores grouped by known standards of dependence, abuse and non-problematic
use. The dependent group consisted of individuals who were recruited from drug and
alcohol treatment centres and met independent clinical evaluation criteria for current
dependence of specific substances. The subjects recruited from primary health care
settings were classified as abusers or non-problematic users according to the presence of
a diagnosis for current abuse on the MINI Plus. ASSIST Scores for Global continuum of
substance use risk, and Specific Substance ASSIST scores for alcohol, cannabis, cocaine,
amphetamines, sedatives and opioids were compared for all three groups using ANOVA
and ROC curves. Results showed that the optimal ASSIST cut-off score for cannabis (the
specific substance of interest in the current study) use and abuse was 0.96 with 91%
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sensitivity, 90% specificity and an ANOVA Scheffe’s differences between groups of 8.1,
p < .001 (Humeniuk & Ali, 2006). An ASSIST cut-off score of 10.5 differentiated
cannabis abuse from cannabis dependence with an AUC of .62, 57% sensitivity, 61%
specificity and an ANOVA Scheffe’s differences between groups of 2.2, p < .001
(Humeniuk & Ali, 2006). Hence the ASSIST can better discriminate use from abuse than
abuse from dependence (Humeniuk & Ali, 2006).
The ASSIST was added to the CAMH Monitor in 2004 and was only employed
for the assessment of cannabis use. The first item asks about lifetime use of cannabis
(cn1). If the participant answers yes to lifetime cannabis use, subsequent items probe
areas such as compulsion to use, problems and failure to function as expected and others
expressing concern about use and attempts to control use are administered. The last
question pertaining to intravenous drug use was excluded from the CAMH Monitor
because of its irrelevance to cannabis use. Therefore, the version of the ASSIST used in
this study consisted of seven rather than eight questions.
Scoring the ASSIST for specific substance involvement consists of summing
participants’ responses to questions two through six. Each question is rated along a fivepoint Likert scale. The scores associated with each response option vary depending on the
question. Question two has response options: 0 ‘never’, 2 ‘once or twice’, 3 ‘monthly’, 4
‘weekly’, and 6 ‘daily or almost daily’. Question three has the same response options but
the numbers associated with each option range instead from 0 to 3, 4, 5 and 6. Similarly
for question 4, yet the numbers are 0, 4, 5, 6 and 7 and likewise for question 5 however
numeric scores are 0, 5, 6, 7 and 8. Question 5 and 6 differ in that the response options
are 0 ‘no, never’, 6 ‘yes, in the past 3 months’ and 3 ‘yes, but not in the past 3 months’.
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Questions two though seven of the ASSIST originally corresponded to Monitor
items ascan1, ascan2, ascan3, ascan4, ascan5 and ascan6 with response options 0-4 (0
‘never’, 1 ‘once or twice’, 2 ‘monthly’, 3 ‘weekly’, 4 ‘daily’). These items were recoded
according to the ASSIST scoring guidelines mentioned above and made into new
variables ascan1 to ascan6. Items ascan1 through ascan6 were then summed to obtain a
cannabis involvement summary score ranging from 0 to 39. A cut-off score of 1.5 for
abuse was used to create the cannabis abuse variable.
2.7.8 Standard questions for alcohol, cannabis and cocaine use. Standard
quantity and frequency questions pertaining to alcohol, cannabis, and cocaine
consumption identical to those used in previous studies by the Addiction Research
Foundation and the Centre for Addiction and Mental Health were included in the
Monitor.
2.7.9 Socio-demographic information. Socio-demographic information relating
to age, sex, level of education, employment status, marital status, annual household
income, and household location were also collected. Age was originally recorded as a
continuous variable and was later divided into four categories according to the 2006
census: 18-24, 25-44, 45-64, and 65+ (agecen4). Male or female sex was recorded (sex).
Level of education was coded as less than high school, completed high school, some
post-secondary education, and university degree (educat4). Employment status was
divided into employed, unemployed, and other (empcat8). Marital status was coded into
three categories: married/living with a partner; previously married (divorced, widowed or
separated); and never married (marstat3) because this was a common method used in the
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literature. Annual household income was divided into 5 categories (hinccat5). Household
location was divided into two categories: rural or urban (rur_urb).
2.8 Secondary Data source
A secondary data source was used for this study. Secondary data are defined as
data that have not been collected for the purpose of this study (Sorenson, Sebroe &
Olsen, 1996). Secondary data sources have numerous advantages as they cost less, save
time, and are usually more representative of the population as they often consist of large
samples. In addition, they have a reduced chance of bias due to the effect of the
diagnostic process or attention caused by the research question (Sorenson et al., 1996).
One of the major disadvantages of secondary data sources is that the researchers do not
control data collection, choice of questions and data quality.
2.9 Data Analysis
All analyses were conducted using Statistical Package for Social Sciences (SPSS) 20.
Variables of interest were selected from the information collected during the interviews
for the 2011 cycle of the CAMH Monitor. All analyses were conducted using appropriate
sampling weights to ensure estimates are representative of the Ontario general
population. All significance (alpha) levels were set at .05.
Use of the Bonferroni correction is still under debate (e.g. Bender & Lange, 1999;
García, 2004; Morgan, 2007; Pernerger, 1998); therefore, multiple comparisons were not
accounted for in the interpretation of results. However, exact p-values are reported so that
readers may adjust for multiple comparisons using the Bonferroni correction of p = .001
for 69 comparisons conducted in this study.

48
2.9.1 Data cleaning and transformation. Prior to all analyses, data were
subjected to data cleaning to locate out-of-range values, univariate outliers and missing
data. The distributions of each variable of interest were examined for normality,
skewness and kurtosis. Data were also inspected for multivariate outliers. Lastly,
variables were also evaluated for multicollinearity and singularity. Diagnostic
information for all variables of interest is presented in Appendix F.
2.9.2 Weighting. Since equal numbers of participants were selected from each of
the six regions in Ontario, weights are required to restore population representation. The
final annualized weight (FWGHT) used in the current study is a function of the selection
weight and a post stratification adjustment.
The quarterly aggregated sampling weight variable (RHHWGTC1‐4) consisted
of four components: the relative household weight (HHWGTC1‐4), which is equal to the
proportion of household residents age 18 and older; the relative region weight
(RWGTC1‐4), which is directly proportional to the percentage of all Ontario households
located in the region; survey quarter (the quarterly sampling interval) and post-strata
adjustments. Cycles are weighted so that each quarterly wave makes an equal
contribution to the weighted N. Quarterly relative household and relative region variables
were summed into cumulative relative household (HHWGTALL) and relative region
(RWGTALL) variables. Finally these variables were aggregated into the cumulative
region-household variable (RHHWGTALL).
In order to reduce bias and adjust for non-response and non-coverage of
households without telephones, probability surveys usually apply post-strata population
adjustments to the base weight according to census information (Casady & Lepkowski,
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1999). The post stratification adjustment was based on eight post-strata representing four
age groups (18-24; 25-44; 45-64; 65+) by sex (male; female) configuration from the 2006
Census (Ialomiteanu & Adlaf, 2011). These adjustments were applied in calculating the
final annualized weight (FWGHT) (Ialomiteanu & Adlaf, 2011). Therefore, the
cumulative regional and household weight (RHHWGTALL) and the post-strata
population adjustment weight (postwtsa) comprise the final annualized weight
(FWGHT) variable used in this study. The final annualized weight (FWGHT) was
applied to all analyses in the current study.
2.10 Descriptive and Bivariate Analyses
2.10.1 Demographic information. Preliminary analyses consisted of calculating
the frequencies and 95% confidence intervals (C.I.s) of all demographic variables for the
entire panel B sample. Demographic variables included in these analyses were: age, sex,
marital status, education, employment, average annual household income and household
location.
2.10.2 Internal consistency of measures. Next, the internal consistency of all
measures used in the study was assessed. The Cronbach’s alpha coefficients and interitem correlations for the ASRS-v1.1 Screener, the GHQ-12, the AUDIT, the cannabisspecific version of the ASSIST and the MINI-APD were calculated.
2.10.3 Mental health in Ontario. The prevalence of psychiatric distress was
estimated by calculating the frequency, proportion and 95% C.I.s of those who scored 4
or more on the GHQ-12. Also, the prevalence of past 12 month anti-anxiety and
antidepressant medication use in Ontario was determined by calculating the frequencies,
proportions and 95% C.I.s for these two variables. The prevalence of ASPD screening
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status in Ontario was established by calculating the frequency, proportion and 95% C.I.
of the ASPD screening status based on a cut-off score of 3 on the MINI-APD.
2.10.4 Substance use in Ontario. Hazardous drinking was defined by a score of
8 or more on the AUDIT. The frequency, proportion and 95% C.I. was calculated. The
frequencies and 95% C.I.s for lifetime, past 12 month and past 3 month cannabis,
marijuana or hash use were calculated along with the frequency, proportion and 95% of
cannabis abuse.. The frequency, proportion and 95% C.I. of lifetime cocaine use were
also calculated.
2.10.5 Adult ADHD screening status prevalence. The prevalence of a positive
screen for adult ADHD in Ontario was estimated by calculating the frequency, proportion
and 95% C.I. of the sample that scored 14 and above on the ASRS-v1.1 Screener
(recommended by Kessler et. al., 2007).
2.10.6 ADHD screening status and demographic variables. Frequencies,
proportions, odds ratios (ORs) for ADHD screening status and all demographic variables
(age, sex, marital status, education, employment, average annual household income and
household location) were calculated along with their 95% C.I.s. Chi-square tests of
independence were also performed when possible to determine whether significant
differences in sex, age, marital status, education, employment, annual household income
or household location existed between those who screened positive and those who
screened negative for ADHD.
2.10.7 Previous ADHD diagnosis and ADHD medication use. Frequencies,
proportions, chi-square tests, ORs and 95% C.I.s were calculated for ADHD screening
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status and previous ADHD diagnosis, as well as previous ADHD medication use, and
ADHD medication use prior to 18 years of age.
2.10.8 Adult ADHD screening status and mental health. Frequencies,
proportions and ORs along with 95% C.I.s were calculated for past 12 month anti-anxiety
medication use, and past 12 month antidepressant use. Chi-square tests of independence
were also performed to examine if any significant differences in psychotropic medication
use existed between those who screened positive and those who screened negative for
ADHD.
ORs and 95% C.I.s were calculated for psychiatric distress and a chi-square test
of independence was executed to determine if any significant differences in psychiatric
distress existed between those who screened positive for ADHD and those who screened
negative for ADHD.
The ORs and 95% C.I.s of the proportion of those who scored three or more on the
ASPD module of the MINI were calculated and a chi-square test of independence was
performed to investigate whether a significant difference existed in ASPD screening
status rates between the ADHD and non-ADHD screened groups. The OR was also
calculated along with its 95% C.I.
2. 10.9 ADHD screening status and substance use. The frequency, proportion ,
OR and 95% C.I. for hazardous alcohol use in both the ADHD positive and the ADHD
negative screening groups were calculated and a chi-square test of independence was
carried out to test for any differences in hazardous alcohol use between the two groups.
Frequencies and proportions of those who screened positive for ADHD and those
who screened negative for ADHD along with the ORs and 95% C.I.s for lifetime, past 12
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month, and past 3 month cannabis use as well as cannabis abuse were calculated. Chisquare tests were performed to test for significant differences between the ADHD
positive and ADHD negative screening groups. The frequencies, proportions, ORs and
95% C.I.s for lifetime cocaine use were also calculated and chi-square tests were
performed to test for significant differences between those in the ADHD positive and
ADHD negative screener groups.
Only crude ORs could be calculated because our sample did not meet the
guidelines for multinomial logistic regression that indicate a minimum of 10 cases per
independent variable (Schwab, 2002). Thus the sample size was too small for the conduct
of adjusted ORs. All the aforementioned analyses were also conducted stratified by sex.
Moreover, differences between males and females who screened positive for ADHD,
between males who screened positive and males who screened negative for ADHD,
between females who screened positive and females who screened negative for ADHD as
well as males and females who screened negative for ADHD were also examined.
2.11 Multivariate Analyses
Research evidence demonstrates that ADHD is a possible risk factor for
psychiatric distress. As indicated in the literature review, a notably large percentage of
individuals with ADHD also have at least one additional mental disorder, most
commonly, depression or anxiety and this association has been observed across a
numerous studies involving different populations.
In the current study ADHD was assumed to precede psychiatric distress (anxiety
and depression). The theory that guided the multivariate model is that proposed by
Biederman & Faraone (2005). These authors state that ADHD may lay the foundation in
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childhood for subsequent adversity- both developmental and environmental, such as
deficits in attention and cognition, learning disabilities, academic failure, deficits in
emotion, fear and aggression regulation, as well as difficulties in parental attachment,
interpersonal relationships, peer rejection and increases in impulsivity and risk-taking
behaviours, all factors which may lead to the development of further psychiatric
impairments in adolescence and adulthood (Biederman & Faraone, 2005). According to
the DSM-IV-TR ADHD is a disorder of early developmental origin, while depression and
anxiety have a later onset (APA, 2000). The onset of depression typically occurs during
adolescence (Hankin, 2005) and increases in prevalence with age (Kessler, 2002).
Ostrander and Herman (2006) found that parent management and locus of control
mediated the relationship between ADHD and subsequent depression in children and
adolescents, thus also modelling ADHD as a precursor to later depression. Also,
depression and anxiety in ADHD may result from sequential mental health issues as for
example; anxiety in ADHD may reflect concerns about competency and performance
(Hankin 2006; Ostrander & Herman, 2006; Schatz & Rostain, 2006).
In the present study, we used hierarchical binary logistic regression to examine
ADHD screening status as a predictor variable for psychiatric distress while controlling
for age, sex, antisocial behaviour screening status and substance use. Table 1.1 displays
all variables of interest in the present study.
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Table 1.1
Study Variables
Variable and Type

Measurement

Exposure Variable
ADHD Screening Status
Dichotomous

Scores of 13 or more on the ASRS-v1.1
1 = Yes
0 = No

Outcome Variable
Psychiatric Distress
Dichotomous

Scores of 4 or more on the GHQ-12 using the
binary scoring method
1 = Yes
0 = No

Demographic Variables
Age
Categorical

1 = 18-24 years old
2 = 25-44 years old
3 = 45-64 years old
4 = 65 + years old

Sex
Nominal

1 = Male
0 = Female

Marital Status
Nominal

1 = Married/Living with a partner
2 = Widowed, divorced, separated
3 = Never married

Education
Ordinal

1 = Less than high school
2 = Completed high school
3 = Some post-secondary education
4 = University degree

Employment Status
Nominal

1 = Employed
2 = Unemployed
3 = Other

Annual Household Income

1 = Less than 30,000
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Ordinal

2 = 30, 000 - 49,000
3 = 50, 000 -79, 000
4 = 80,000 +

Household Location
Dichotomous

1 = Urban
0 = Rural

Past 12 Month Anti-anxiety
Medication Use
Dichotomous

1 = Yes
0 = No

Past 12 Month Antidepressant Use
Continuous

1 = Yes
0 = No

Antisocial Personality Disorder
screening status
Dichotomous

Scores of 6 or more on the MINI-APD
1 = Yes
0 = No

Substance Use Variables
Hazardous Alcohol Use
Dichotomous
Lifetime Cannabis, Marijuana
or Hash Use
Dichotomous

Scores of 8 or more on the AUDIT
1 = Yes
0 = No
1 = Yes
0 = No

Past 12 Month Cannabis, Marijuana
or Hash Use
1 = Yes
Dichotomous
0 = No
Past 3 Month Cannabis, Marijuana
or Hash Use
Dichotomous

1 = Yes
0 = No

Cannabis Abuse
Dichotomous

Scores of 1.5 or more on the ASSIST
1 = Yes
0 = No

Lifetime Cocaine Use
Dichotomous

1 = Yes
0 = No
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Chapter 3: Results
3.1 Description of the Study Sample
A sample of 3039 Ontarians met eligibility criteria for this study (Panel A = 1040
and Panel B = 1999). However, only Panel B of the CAMH Monitor was selected for
analyses as it comprised the items of interest in the current study. Therefore, all analyses
were conducted on a weighted sample of 1999 individuals from the general population of
Ontario. Only weighted results are reported herein.
The mean age of participants was 47 years old (SD = 17). When age was divided
into four categories, the largest group based on numeric size was those between the ages
of 25 to 44 years old while those 18 to 24 years old comprised the smallest age group.
Slightly more than half (53%) of the sample was female. The majority of the sample
(68%) were married or living with a partner. Over two thirds of the sample reported
having some post-secondary education (35%) or a university degree (35%). The large
majority of respondents (85%) lived in an urban area. Descriptive statistics for the full
sample (Panel B) are presented below in Table 3.1.
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Table 3.1
Descriptive Statistics for Demographic Variables (Panel B)
Variable

Freq.

Proportion (%) [95% C.I]

Age (4 categories)
18-24

210

10.56

[9.27, 12.03]

25-44

747

37.58

[35.48, 39.79]

45-64

646

32.53

[30.48, 34.65]

65 +

324

16.29

[14.73, 18.03]

942

47.55

[45.22, 49.65]

1044

52.56

[50.35, 54.78]

1353

68.12

[66.02, 70.17]

Previously married

210

10.57

[9.27, 12.03]

Never married

404

20.36

[18.60, 22.19]

< High school

193

9.71

[8.47, 11.13]

Completed high school

398

20.02

[18.31, 21.88]

Some post-secondary

688

34.61

[32.55, 36.79]

University degree

693

34.86

[32.80, 37.04]

1281

64.80

[62.64, 66.90]

85

4.30

[3.47, 5.31]

Sex
Male
Female
Marital Status
Married/ Living with a partner

Education

Employment
Employed
Unemployed
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Other

611

30.91

[28.89, 33.01]

Annual Household Income
< 30,000

169

8.51

[7.34, 9.85]

30,000-49,000

223

11.23

[989, 12.72]

50,000-79,000

368

18.53

[16.86, 20.33]

80,000 +

764

38.47

[36.33, 40.66]

Don’t know/Refused

462

23.26

[21.43, 25.19]

Rural

301

15.16

[13.63, 16.83]

Urban

1686

84.89

[83.22, 86.42]

Household Location
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3.2 Internal Consistency Reliability of Measures: Cronbach’s Alphas
The alpha coefficients for the ASRS-v1.1 Screener, the GHQ-12, the MINI-APD,
the AUDIT and the ASSIST are presented in Table 3.2.1 below.
Table 3.2.1
Cronbach’s Alphas and Inter-Item Correlations of the ASRS-v1.1 Screener, the GHQ-12,
the MINI APD, the AUDIT and the ASSIST
Measure

Alpha

Mean

Min.

Max.

Range

Variance N of Items

ASRS-v1.1 Screener

.75

0.35

0.23

0.59

0.36

0.01

6

GHQ-12

.82

0.27

0.04

0.57

0.53

0.02

12

MINI-APD

.73

0.03

0.00

0.12

0.12

0.00

11

AUDIT

.78

0.35

0.14

0.67

0.53

0.02

10

ASSIST

.72

0.27

0.09

0.54

0.45

0.02

7

3.3 Descriptive Statistics and Population Proportions for Mental Health and
Substance Use Variables (Full Panel B Sample)
3.3.1 Psychiatric Distress. Using the GHQ-12 with a cut-off value of 4, the
prevalence of psychiatric distress in the Ontario population was 9.93% [8.66, 11.34]. The
overall mean GHQ-12 score was 1.05 (SD = 2.05).
3.3.2 Past 12 month anti-anxiety medication use and past 12 month
antidepressant use. The prevalence of past 12 month anti-anxiety medication use in the
Ontario population was 7.06% [5.99, 8.30] and similarly, the prevalence of past 12 month
antidepressant use in the Ontario population was 7.07% [6.00, 8.31].
3.3.3 Antisocial personality disorder screening status in Ontario. Using a cutoff score of five or more, approximately 0.71% [0.40, 1.21] of the Ontario population
screened positive for antisocial personality disorder on the MINI-APD.
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3.3.4 Hazardous alcohol use in Ontario. The prevalence of hazardous alcohol
use in Ontario, as defined by a score of eight or more on the AUDIT, was approximately
13.06% [11.61, 14.66].
3.3.5 Cannabis, marijuana and hash use and abuse in Ontario. As shown in
Table 3.3.6 below, approximately 41% of the population had used cannabis, marijuana or
hash at least once in their lifetime. In addition, roughly 14% had used cannabis,
marijuana or hash over the past 12 months, and nearly 10% reported using cannabis,
marijuana or hash over the past three months. In their validation study of the ASSIST, the
WHO suggested that scores of 1.5 or more best delineated cannabis use versus cannabis
abuse (Humeniuk & Ali, 2006). Using this cut-off value, approximately 9% of the
Ontario population screened positive for cannabis abuse.
Table 3.3.5
Cannabis Use in Ontario
Time Period

Freq.

Proportion (%)

[95% C.I.]

Lifetime

799

40.21

[38.31, 42.69]

Past 12 months

272

13.81

[12.33, 15.43]

Past three months

188

9.47

[8.24, 10.86]

Yes

181

9.15

[7.93, 10.93]

No

1797

90.85

[89.47, 92.07]

Cannabis Abuse

3.3.6 Lifetime cocaine use in Ontario. Approximately 7.03% [5.96, 8.27] of the
Ontario population have used cocaine at least once in their lifetime.
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3.4 Description of the Study Population According to ADHD Screener Status
3.4.1 Prevalence of adult ADHD screener status. As previously mentioned, the
ASRS v1.1 Screener is comprised of six questions reflecting the impairments common in
adult ADHD. Response options are rated on a five-point Likert scale as follows: 0
‘never’, 1 ‘rarely’, 2 ‘sometimes’, 3 ‘often’, and 4 ‘very often’. Summary scores have a
possible range from 0-24. Kessler et al. (2007), the developers of the measure, proposed
an optimal case finding threshold of 13/14, meaning that scores less than or equal to 13
are considered ADHD negative and scores of 14 or more are considered ADHD positive.
Using this cut point, 3.47% [2.73, 4.40] of Ontario adults screened positive for ADHD on
the ASRS v1.1Screener.
3.4.2 The association of age and ADHD screener status. The average age of
those who screened positive for adult ADHD was 35.59 years (SD = 14.64) and 46.84
years (SD = 17.03) for those who screened negative for ADHD. Positive ADHD Screener
status was highest among those 18-24 years of age and lowest among those in the 65+
category. The relationship between ADHD Screener status and age was significant, χ2 (df
= 3, N = 1926) = 11.48, p = .009.
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Table 3.4.2
Frequencies and Proportions for Age According to ADHD Screener Status
ADHD Positive (N = 69)
Freq. Proportion (%) [95% C.I.]

ADHD Negative (N =1857)
Freq. Proportion (%) [95% C.I.]

Age
18-24

13

18.84

[10.79, 30.42]

197

10.61

[9.26, 12.12]

25-44

31

44.92

[33.10, 57.32]

716

38.56

[36.35, 40.82]

45-64

22

31.88

[21.47, 44.33]

624

33.60

[31.46, 35.81]

65 +

3

4.35

[1.13, 13.01]

320

17.23

[15.55, 19.04]

3.4.3 Sex and ADHD screener status. As shown in Table 3.4.3, the proportion of
men and women in both the ADHD positive and ADHD negative groups were
approximately equal. No significant relationship between sex and ADHD Screener status
was found, χ2 (df =1, N = 1988) = 0.29, p = .591.
Table 3.4.3
Frequencies and Proportions for Sex According to ADHD Screener Status
ADHD Positive (N = 70)
Freq. Proportion (%) [95% C.I.]

ADHD Negative (N =1918)
Freq. Proportion (%) [95% C.I.]

Male

31

44.29

[32.60, 56.61]

912

47.55

[45.30, 48.81]

Female

39

55.71

[43.39, 67.40]

1006

52.45

[50.19, 54.70]
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3.4.4 Marital status and ADHD screener status. The relationship between
marital status and ADHD Screener status was significant, χ2 (df = 2, N = 1967) = 12.34, p
= .002. Based on examination of the standardized residuals, individuals with ADHD
positive screen were more likely to have never been married (see Table 3.4.4 below).
Table 3.4.4
Frequencies and Proportions for Marital Status and ADHD Screener Status
ADHD Positive (N = 69)
Freq. Proportion (%) [95% C.I.]

ADHD Negative (N =1898)
Freq. Proportion (%) [95% C.I.]

Marital Status
Married/
Partner
Widowed/
Separated/
Divorced
Never
Married

35

50.72

[38.51, 62.85]

1318

69.44

[67.33, 71.47]

9

13.04

[6.50, 23.82]

201

10.59

[9.26, 12.08]

25

36.23

[25.25, 48.75]

379

19.97

[18.21, 21.86]

3.4.5 Education and ADHD screener status. The majority of individuals in both
ADHD screening status groups reported having some post-secondary education or a
university degree (see Table 3.4.5). Also, roughly 10% of both groups had not completed
high school. No relationship between education and ADHD screener status was found, χ2
(3, N = 1971) = 2.91, p = .406.
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Table 3.4.5
Frequencies and Proportions for Education According to ADHD Screener Status
ADHD Positive (N = 67)

ADHD Negative (N = 1904)

Freq. Proportion (%) [95% C.I.]

Freq. Proportion (%) [95% C.I.]

Education
< High school

9

13.43

[6.70, 24.47]

184

9.66

[8.39, 11.10]

13

19.40

[11.12, 31.24]

385

20.22

[18.45, 22.11]

Some
post-secondary 27

40.30

[28.72, 53.00]

660

34.66

[32.53, 36.85]

University
degree

26.87

[17.11, 39.31]

675

35.45

[33.31, 37.65]

Completed
high school

18

3.4.6 Employment and ADHD screener status. Table 3.4.6 shows the
proportions for each category of employment according to ADHD Screener status. No
significant difference in employment status between those who screened positive for
ADHD and those who screened negative for ADHD was found, χ2 (2, N = 1977) = 2.55, p
= .279.

65
Table 3.4.6
Frequencies and Proportions for Employment Status According to ADHD Screener
Status
ADHD Positive (N = 68)
Freq. Proportion (%) [95% C.I.]

ADHD Negative (N =1908)
Freq. Proportion (%) [95% C.I.]

Employment
Status
Employed

48

68.57

[56.23, 78.85]

1233

64.66

[62.46, 66.80]

5

7.14

[2.66, 16.56]

80

4.20

[3.36, 5.22]

Other

17

24.29

[15.17, 36.27]

594

31.15

[29.09, 33.29]

Total

70

100.00

-

1907

100.00

-

Unemployed

3.4.7 Annual Household Income and ADHD screener status. As Table 3.4.7
indicates, similar proportions of individuals in both the ADHD positive (35%) and
ADHD negative (39%) screen groups had an average household income of more than
80,000 dollars a year. No significant difference in average annual household income was
found between the two groups, χ2 (df = 4, N = 1986) = 4.67, p = .323.

66
Table 3.4.7
Frequencies and Proportions for Annual Household Income According to ADHD
Screener Status
ADHD Positive (N = 69)
Freq. Proportion (%) [95% C.I.]

ADHD Negative (N =1917)
Freq. Proportion (%) [95% C.I.]

Annual Household
Income Range
< 30,000

9

13.04

[6.50, 23.82]

160

8.35

[7.17, 9.70]

30,000-49,000

9

13.04

[6.50, 23.82]

214

11.16

[9.80, 12.68]

50,000-79,000

16

23.19

[14.22, 35.18]

352

18.36

[16.67, 20.18]

80,000 +

24

34.78

[23.98, 47.28]

740

38.60

[36.42, 40.83]

Don’t know/
Refused

11

15.94

[8.60, 27.16]

451

23.53

[21.66, 25.51]

3.4.8 Household location and ADHD screener status. The majority of both the
ADHD positive (87%) and ADHD negative (85%) groups lived in an urban area. No
significant relationship between household location and ADHD Screener status was
found, χ2 (1, N = 1986) = 0.237, p = .626. Household location according to ADHD
Screener status is presented in Table 3.4.8 below.
Table 3.4.8
Frequencies and Proportions for Household Location According to ADHD Status
ADHD Positive (N = 69)
Freq. Proportion (%) [95% C.I.]

ADHD Negative (N =1917)
Freq. Proportion (%) [95% C.I.]

Location
Urban

60

86.96

[76.18, 93.50]

1626

84.82

[83.12, 86.38]

Rural

9

13.04

[6.50, 23.82]

291

15.18

[13.62, 16.88]
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3.5 Descriptive Statistics and Population Proportions for Mental Health and
Substance Use Variables by ADHD Screener Status
3.5.1 Previous ADHD diagnosis by ADHD screener status. Among those who
screened positive for ADHD on the ASRS v1.1 Screener, 10.14% [4.52, 20.37] had
previously been diagnosed with ADHD by a healthcare professional. In addition, 2.40%
[1.78, 3.22] of those who screened negative for ADHD had previously been diagnosed
with ADHD by a healthcare professional.
A separate cross-tabulation was conducted to disaggregate previous ADHD
diagnosis according to age. Results showed that the vast majority of those previously
diagnosed with ADHD were under the age of 44 with 49.02% [34.95, 63.23] belonging to
the 25 to 44 year old age group, followed by 37.25% [24.47, 51.94] in the 18 to 24 year
old age group, and 11.76% [4.87, 24.55] in the 45 to 64 year old age group. Only 1.96%
[0.10, 11.79] of those who had previously been diagnosed with ADHD belonged to the
65 and over age group. Furthermore, previous ADHD diagnoses were most prevalent
among those aged 18-24 years of age (9.05%) [5.68, 13.98], followed by those aged 25 to
44 years old (3.36%) [2.23, 4.99], those 45 to 64 years old (0.93) [0.38, 2.12], and those
aged 65 and over (0.31) [0.02, 1.99].
3.5.2 Previous ADHD medication use and ADHD screener status. Of those
previously diagnosed with ADHD, 83.33% [36.48, 99.12] were treated with prescription
medication for the disorder. In addition, of those previously diagnosed and treated with
prescription medication for ADHD, 66.67% [24.11, 94.00] had been treated with ADHD
medication before the age of 18. Furthermore, none of these individuals had been treated
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with ADHD medication in the past 12 months nor was anyone in the sample currently
taking/prescribed ADHD medication.
3.5.3 Anti-anxiety and antidepressant medication use and ADHD screener
status. As shown in Table 3.5.4, about 40% of the ADHD positive group and
approximately 6% of the ADHD negative group had taken prescription medication to
reduce anxiety and panic attacks in the past 12 months. Of those who had taken antianxiety medication in the past year, 20.00% [13.91, 27.78] had an ADHD positive screen.
There was a significant association between anti-anxiety medication use over the past 12
months and ADHD screening status, χ2 (1, N = 1984) = 120.07, p = .000. Individuals who
screened positive had higher odds of past 12 month anti-anxiety medication use than
those who screened negative for ADHD (OR = 10.73; 95% CI = 6.41, 17.95).
Antidepressant medication use in the last year according to ADHD screener status
is also presented in Table 3.5.4. Approximately 36% of those who screened positive for
ADHD reported taking prescription medication to treat depression in the past 12 months,
whereas about 6% of those who screened negative for ADHD reported taking such
medication in the past 12 months. Of those who had taken antidepressants in the last year,
17.86% [12.10, 25.43] screened positive for ADHD. Antidepressant medication use in the
past 12 months differed significantly by ADHD status, χ2 (1, N = 1980) = 92.52, p = .000,
with the ADHD positive group having higher odds of antidepressant medication in the
past year (OR = 8.87; 95% CI = 5.25, 15.01).
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Table 3.5.3
Psychotropic Medication Use by ADHD Screener Status
ADHD Positive
Freq. (%)

ADHD Negative

[95% C.I.]

Freq.

(%) [95% C.I.] χ2

df

p-value

Anti-anxiety
Yes

28

40.00 [28.69, 52.41]

112

No

42

60.00 [47.59, 71.31]

1802

Total

70 100.00

-

5.85

[4.86, 7.02]

94.15 [92.98, 95.14]

1914 100.00

120.07 1 < .000

Antidepressants
Yes

25

36.23

[25.25, 48.75]

115

No

44

63.77

[51.25, 74.75]

1796

Total

69 100.00

-

6.00

[5.02, 7.21]

93.08 [92.79, 94.98]

1911 100.00

92.52 1 < .000

3.5.4 Psychiatric distress according to ADHD screener status. Psychiatric
distress differed significantly by ADHD Screener status, (χ2 (1, N = 1986) = 90.10, p =
.000), with those in the ADHD positive group being more likely to have psychiatric
distress than those in the ADHD negative group (43.48% [31.77, 55.92] versus 8.71%
[7.50, 10.08] respectively). Moreover, those in the ADHD positive group had higher odds
of psychiatric distress (OR = 8.06; 95% CI = 4.88, 13.31) compared to the non-ADHD
group. Those who screened positive for ADHD represented 15.23% [10.67, 21.19] of all
those who screened positive for psychiatric distress.
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3.5.5 Antisocial Personality Disorder screener status and ADHD screener
status. Of those who screened positive for ADHD, 8.82% [3.64, 18.85] screened positive
for ASPD, whereas 0.42% [0.19, 0.86] of those who screened negative for ADHD
screened positive for ASPD. Of all those who screened positive for ASPD, 42.86%
[18.82, 70.35] also had ADHD. ASPD screening status differed significantly by ADHD
screening status, χ2 (1, N = 1951) = 64.98, p = .000. Those who screened positive for
ADHD had higher odds of screening positive for ASPD (OR = 22.68; 95% CI = 7.64,
67.35).
3.5.6 Hazardous alcohol use and ADHD screener status. As seen in Table
3.5.6, a significant association between ADHD screening status and hazardous alcohol
use as measured by the AUDIT was found, χ2 (1, N = 1938) = 10.25, p = .001. The
ADHD positive group had higher odds of hazardous alcohol use than the ADHD negative
group (OR = 2.41; 95% CI = 1.38, 4.18). Of those in the ADHD positive group,
approximately 26% screened positive for hazardous alcohol use on the AUDIT, whereas
half that amount (about 13%) of the ADHD negative group screened positive for
hazardous alcohol use on the AUDIT.
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Table 3.5.6
Hazardous Alcohol Use (AUDIT 8+) and ADHD Screener Status
ADHD Positive
Freq. (%)

[95% C.I.]

ADHD Negative
Freq. (%)

[95% C.I.]

χ2

df

p-value

Hazardous
Alcohol Use
Yes

18

25.71

[16.74, 37.78]

235 12.58 [11.13, 14.19]

No

52

74.29 [62.22, 83.66] 1633 87.42 [85.81, 88.87]
10.25

1

.001

3.5.7 Cannabis, marijuana and hash use and abuse according to ADHD
screener status. As shown in Table 3.5.7 below, roughly 73% of those who screened
positive for ADHD and approximately 39% of those who screened negative for ADHD
reported using cannabis, marijuana or hash in their lifetime. Lifetime cannabis, marijuana
or hash use differed significantly by ADHD status, χ2 (1, N = 1974) = 31.58, p = .000.
Those in the ADHD positive had higher odds of lifetime cannabis, marijuana or hash use
compared to the ADHD negative group (OR = 4.15; 95% CI = 2.43, 7.08).
Cannabis use over the past 12 months is also presented in Table 3.5.7.
Approximately 26% of those in the ADHD positive group compared to 13% of the
ADHD negative group have used cannabis, marijuana or hash in the past 12 months. Past
12 month cannabis, marijuana or hash use differed significantly by ADHD screener
status, χ2 (1, N = 1970) = 9.06, p = .003, with those in the ADHD positive group having
higher odds of past 12 month cannabis, marijuana or hash use compared to the ADHD
negative group (OR = 2.29; 95% CI = 1.32, 3.98).
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However, the association between cannabis, marijuana or hash use over the past
three months and ADHD screener status was not significant, χ2 (1, N = 1985) = 3.49, p =
.062, with about 16% of the ADHD positive group and 9% of the ADHD negative group
reported using cannabis, marijuana or hash in the past three months. About 15% of those
who screened positive for ADHD and roughly 9% of those who screened negative for
ADHD screened positive for cannabis abuse. Those who screened positive for ADHD
were no more likely than those in those who screened negative for ADHD to screen
positive for cannabis abuse, χ2 (1, N = 1978) = 2.61, p = .106. Frequencies, proportions,
and 95% confidence intervals for lifetime, past 12 month, and past three month cannabis,
marijuana and hash use, and cannabis abuse stratified by ADHD screener status are
presented in Table 3.5.7 below.
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Table 3.5.7
Cannabis Use and ADHD Screener Status
ADHD Positive
Freq. Prop. (%) [95% C.I.]

ADHD Negative
χ2 df p-value

Freq. Prop. (%) [95% C.I.]

Lifetime
Yes

51

72.86

[62.22, 83.66]

748

39.29

[37.09, 41.53]

No

19

27.14

[17.52, 39.30]

1156

60.71

[58.47, 62.91]
31.58 1

.000

Past 12 months
Yes

18

26.09

[16.59, 38.28]

254

13.36

[11.88, 14.99]

No

51

73.91

[61.72, 83.31]

1647

86.64

[85.01, 88.12]
9.06 1 .003

Past 3 months
Yes

11

15.94

[8.60, 27.16]

177

9.24

[8.00, 10.65]

No

58

84.06

[72.84. 91.40]

173

90.76

[89.35, 92.00]
3.49 1 .062

Cannabis
Abuse
Yes

10

14.71

[7.66, 25.85]

171

No

58

85.29

[74.15, 92.34] 1739

8.95

[7.73, 10.34]

91.05 [89.66, 92.27]
2.61 1 .106

3.5.8 Lifetime cocaine use according to ADHD screener status. Approximately
twenty-three percent (23.19%) [14.22, 35.18] of those who screened positive for ADHD
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and 6.36% [5.33, 7.57] of those who screened negative for ADHD reported using cocaine
in their lifetime. Also, 11.59% [6.98, 18.42] of those who used cocaine in their lifetime
screened positive for ADHD. A significant relationship between lifetime cocaine use and
ADHD screener status was found, χ2 (3, N = 1986) = 29.40, p = .000, with the ADHD
positive group having higher odds of lifetime cocaine use than the ADHD negative group
(OR = 4.42; 95% CI = 2.45, 7.96).
3.6 Summary of Key Findings
The prevalence of positive adult ADHD screen was found to be approximately
3.47% using the ASRS v1.1 Screener. Descriptive analyses of demographic variables
comparing those who screened positive for ADHD on the ASRS v1.1 Screener to those
who did not revealed that men and women are equally likely to screen positive for
ADHD and that the rates of a positive adult ADHD screen appear to be highest among
those 18-24 years old and lowest among those 65 and over. Those who screen positive for
ADHD appear to be more likely to have never been married. The rates of full-time
employment were similar between the two groups, however, a larger proportion of those
who screened positive for ADHD reported being unemployed or endorsed ‘other’ (being
on social assistance or having an alternative form of income) as their category of
employment. Furthermore, no significant differences in education, annual household
income or household location were found.
Only about 10% of those who screened positive for ADHD reported being
previously diagnosed with ADHD by a healthcare professional, the majority of who were
under the age of 44. Most of those who had a previous diagnosis of ADHD reported
being treated with prescription medication for the disorder, with treatment starting before
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the age of 18 in a substantial proportion of cases. High rates of anti-anxiety and
antidepressant medication use was found among those who screened positive for ADHD
with correspondingly high rates of psychiatric distress being reported among the ADHD
positive group as well. Significantly higher rates of ASPD positive screen were also
reported in the ADHD positive group. Significantly elevated rates of hazardous alcohol
use, lifetime and past 12 month cannabis use were also found among those who screened
positive for ADHD. However, no significant differences in past three month cannabis use
or cannabis abuse were found between the groups.
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Chapter 4: Sex and ADHD Screener Status
4.1 Sex, ADHD Screener Status and Previous ADHD Diagnosis
No significant differences in previous ADHD diagnosis were found between men
and women who screened positive for ADHD. Women who screened positive for ADHD
however, were more likely to have a previous diagnosis of ADHD than women who
screened negative for ADHD, χ2 (1, N = 1041) = 24.25, p = .000. Among those who
screened negative for ADHD, men were more likely to have previously been diagnosed
than women, χ2 (1, N = 1909) = 17.87, p = .000. No significant difference in previous
ADHD diagnosis was found between men and women who screened positive for ADHD,
χ2 (1, N = 70) = 0.01, p = .936.
4.2 Sex and Previous ADHD Medication Use
Of those previously diagnosed, 74.36% [57.57, 86.40] of males and 76.92%
[45.98, 43.84] of females were treated with ADHD medication and no significant
difference in ADHD medication use between sexes was found, χ2 (1, N = 52) = 0.34, p =
.853. Of those previously diagnosed and treated with medication, none had been treated
with medication in the past 12 months. Furthermore, of those previously diagnosed and
treated with medication, 86.21% [67.43, 95.49] of men were treated with medication
before the age of 18 and 54.55% [24.57, 81.87] of women were treated with ADHD
medication before the age of 18. A significant difference in ADHD medication use prior
to age 18 between men and women was found, χ2 (1, N = 4) = 4.59, p = .032.
4.3. Sex, ADHD Screener Status and Anti-anxiety Medication Use
4.3.1 ADHD screener status and anti-anxiety medication use among men.
Past year anti-anxiety medication use was present among 30.00% [15.41, 49.56] of men

77
who screened positive for ADHD and 4.51% [3.29, 6.12] of men who screened negative
for ADHD. Moreover, men who screened positive for ADHD represented 18.00% [9.05,
31.92] of those who had reported taking anti-anxiety medication in the past year. Past
year anti-anxiety medication use among men differed significantly by ADHD screener
status, χ2 (1, N = 939) = 37.43, p = .000. Men who screened positive for ADHD had
higher odds of past year anti-anxiety medication use than men who screened negative for
ADHD (OR = 9.07; 95% CI = 3.91, 21.05).
4.3.2 ADHD and anti-anxiety medication use among women. Among women
in the positive ADHD screener group, 47.37% [31.31, 63.95] reported taking anti-anxiety
medication in the past year compared to 52.63% [36.05, 68.69] who had not. Among
women in the negative ADHD screener status group, 7.07% [5.60, 8.88] reported taking
anti-anxiety medication in the past year compared to 92.93% [91.12, 94.40] that had not.
Also, 20.22% [12.73, 30.33] of women who reported taking anti-anxiety medication in
the past year screened positive for ADHD. A significant association was found between
ADHD screener status and anti-anxiety medication use among women, χ2 (1, N = 1042) =
76.11, p = .000, with women who screened positive for ADHD having higher odds of
past 12 month anti-anxiety medication use compared to women who screened negative
for ADHD (OR = 11.83; 95% CI = 5.99, 23.37).
4.3.3 Anti-anxiety medication use among men and women who screened
negative for ADHD. Of those who screened negative for ADHD and who reported
taking anti-anxiety medication in the past year, 36.61% [27.86, 46.29] were men and
63.39% [53.71, 72.14] were women. A significant relationship was found between sex
and past year anti-anxiety medication use among those who screened negative for
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ADHD, χ2 (1, N = 1913) = 5.68, p = .017. Women who screened negative for ADHD had
higher odds of past 12 month anti-anxiety medication use compared to men who screened
negative for ADHD (OR = 1.61; 95% CI = 1.09, 2.39).
4.3.4 Anti-anxiety medication use among men and women who screened
positive for ADHD. Thirty percent [15.41, 49.56] of men and 47.40% [31.31, 63.95] of
women who screened positive for ADHD reported taking anti-anxiety medication in the
past year. No significant difference in anti-anxiety medication use between men and
women who screened positive for ADHD was found, χ2 (1, N = 68) = 2.11, p = .146.
4.4. Sex, ADHD Screener Status and Antidepressant Medication Use
4.4.1 ADHD screener status and antidepressant medication use among men.
Among men who screened positive for ADHD, 25.81% [12.54, 44.93] reported taking
antidepressant medication in the past year and 4.29% [3.11, 5.87] of men who screened
negative for ADHD reported taking antidepressant medication in the past year. Also, men
who screened positive for ADHD represented 17.02% [8.14, 31.35] of all men who had
reported taking antidepressants in the past year. There was a significant relationship
between antidepressant medication use among men and ADHD screener status, χ2 (1, N =
940) = 29.22, p = .000. Men who screened positive for ADHD had higher odds of taking
antidepressants in the past 12 months compared to men who screened negative for
ADHD (OR = 7.76; 95% CI = 3.26, 18.45).
4.4.2 ADHD Screener status and antidepressant medication use among
women. Antidepressant medication use over the past year was prevalent among 46.15%
[30.43, 62.62] of women who screened positive for ADHD and 7.55% [6.03, 9.40] of
women who screened negative for ADHD. In addition, women who screened positive for
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ADHD represented 19.15% [12.04, 28.84] of all women who reported taking
antidepressants in the past year. Past year antidepressant medication use among women
differed significantly by ADHD screener status, χ2 (1, N = 1041) = 67.98, p = .000, with
women who screened positive for ADHD having higher odds of past 12 month
antidepressant use than women who screened negative for ADHD (OR = 10.44, 95% CI
= 5.34, 24.44).
4.4.3 Antidepressant use among men and women who screened negative for
ADHD. Past year antidepressant medication use was prevalent among 4.29% [3.11, 5.87]
of men and among 7.55% [6.03, 9.40] of women who screened negative for ADHD. Of
all those who screened negative for ADHD and who reported taking antidepressants in
the past year, 33.91% [25.51, 43.40] were men and 66.09% [56.60, 74.49] were women.
There was a significant association between sex and past year antidepressant use among
those screening negative for ADHD, χ2 (1, N = 1911) = 9.15, p = .002, with women
having higher odds of past 12 month antidepressant use than men (OR = 1.83; 95% CI =
1.23, 2.72).
4.4.4 Antidepressant medication use among men and women who screened
positive for ADHD. Past year antidepressant use was prevalent among 25.81% [12.54,
44.93] of men and 46.15% [30.43, 62.62] of women who screened positive for ADHD.
No significant difference in past year reported antidepressant use was found between men
and women who screened positive for ADHD, χ2 (1, N = 70) = 3.06, p = .080.
4.5 Sex, ADHD Screener status and Psychiatric Distress
4.5.1 ADHD screener status and psychiatric distress among men. A larger
proportion of men who screened positive for ADHD than men who screened negative for
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ADHD screened positive for psychiatric distress (35.48% [19.83, 54.62] versus 7.46%
[5.88, 9.41] respectively). Moreover, of all men who screened positive for psychiatric
distress, 13.92% [7.48, 23.97] also screened positive for ADHD. Psychiatric distress, as
measured by the GHQ-12, among men differed significantly by ADHD screener status, χ2
(1, N = 942) = 30.64, p = .000, with men who screened positive for ADHD having higher
odds of psychiatric distress than men who screened negative for ADHD (OR = 6.82; 95%
CI =3.14, 14.82).
4.5.2. ADHD screener status and psychiatric distress among women.
Psychiatric distress was present among 48.72% [32.71, 64.97] of women who screened
positive for ADHD and in 9.84% [8.10, 11.89] of women who screened negative for
ADHD. Of all women who screened positive for psychiatric distress, 16.10% [10.21,
24.26] also screened positive for ADHD. A significant association between psychiatric
distress and ADHD screener status was found among women, χ2 (1, N = 1045) = 56.65, p
= .000, with women who screened positive for ADHD having higher odds of psychiatric
distress than women who screened negative for ADHD (OR = 8.70; 95% CI = 4.49,
16.86).
4.5.3 Psychiatric distress among men and women who screened negative for
ADHD. Approximately 9.84% [8.10, 11.89] of women who screened negative for ADHD
and 7.46% [5.88, 9.41] of men who screened negative for ADHD had psychiatric distress.
Among those who screened positive for psychiatric distress, 40.72% [33.27, 48.60] were
men and 59.28% [51.40, 66.73] were women. No significant difference in psychiatric
distress between men and women who screened negative for ADHD was found, χ2 (1, N
= 7) = 3.40, p = .065.
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4.5.4 Psychiatric distress among men and women who screened positive for
ADHD. Among those who screened positive for ADHD, 35.48% [19.83, 54.62] of men
and 48.72% [32.71, 64.97] of women screened positive for psychiatric distress. Among
all those who screened positive for psychiatric distress, 63.33% [43.90, 79.45] of men
also screened positive for ADHD and 36.67% [20.55, 56.10] of women also screened
positive for ADHD. No significant difference in psychiatric distress between men and
women who screened positive for ADHD was found, χ2 (1, N = 70) = 1.24, p = .266.
4.6 Sex, ADHD Screener Status and Antisocial Personality Disorder (ASPD)
Screener Status
4.6.1 ADHD screener status and ASPD screener status among men.
Approximately 20.00% [9.51, 37.31] of men who screened positive for ADHD also
screened positive for ASPD, whereas 0.90% [0.42, 1.84] of men who screened negative
for ADHD also screened positive for ASPD. Of those who screened positive for ASPD,
42.86% [18.82, 70.35] screened positive for ADHD and 57.14% [29.65, 81.18] did not. A
significant association between ASPD screener status and ADHD screener status in men
was found, χ2 (1, N = 915) = 70.23, p = .000, with men who screened positive for ADHD
having higher odds screen of screening positive for ASPD than men who screened
negative for ADHD (OR = 27.41; 95% CI = 8.82, 85.14). No women screened positive
for ASPD in this sample.
4.7 Sex, ADHD Screener Status and Hazardous Alcohol Use
4.7.1 ADHD screener status and hazardous alcohol use among men. Similar
proportions of men who screened positive for ADHD and men who screened negative for
ADHD screened positive for hazardous alcohol use as measured by the AUDIT (25.81%
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[12.54, 44.93] versus 18.72% [16.22, 21.50], respectively). ADHD was prevalent among
4.65% [2.18, 9.26] of all men who screened positive for hazardous alcohol use. No
significant difference in hazardous alcohol use between men who screened positive for
ADHD and men who screened negative for ADHD was found, χ2 (1, N = 907) = 0.98, p =
.323.
4.7.2 ADHD screener status and hazardous alcohol use among women.
Among women, 23.68% [12.02, 40.61] of those who screened positive for ADHD and
7.16% [5.67, 8.99] of those who screened negative for ADHD screened positive for
hazardous alcohol use. Of all women who screened positive for hazardous alcohol use,
11.25% [5.59, 20.76] also screened positive for ADHD. Hazardous alcohol use among
women differed significantly by ADHD screener status, χ2 (1, N = 1030) = 13.95, p =
.000. Women who screened positive for ADHD had higher odds of hazardous alcohol use
than women who screened negative for ADHD (OR = 4.03 95% CI = 1.84, 8.83).
4.7.3 Hazardous alcohol use among men and women who screened negative
for ADHD. A larger proportion of men who screened negative for ADHD than women
who screened negative for ADHD screened positive for hazardous alcohol use (18.72%
[16.22, 21.50] versus 7.16% [5.67, 8.99]). Also, of all those who screened positive for
hazardous alcohol use, 67.98% [63.42, 75.50] were men. A significant relationship
between sex and hazardous alcohol use among men and women who screened negative
for ADHD was found, χ2 (1, N = 1868) = 56.57, p = .000, with men having higher odds of
hazardous alcohol use compared to women (OR = 2.99; 95% CI = 2.22, 4.01).
4.7.4 Hazardous alcohol use among men and women who screened positive
for ADHD. A similar proportion of men who screened positive for ADHD (25.81%)
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[12.54, 44.93] and women who screened positive for ADHD (23.68%) [12.02, 40.61]
also screened positive for hazardous alcohol use. Of all those who screened positive for
ADHD and hazardous alcohol use, 47.06% [23.86, 71.47] were men and 52.94% [28.53,
76.14] were women. No significant sex difference in hazardous alcohol use among those
who screened positive for ADHD was found, χ2 (1, N = 69) = 0.04, p = .839.
4.8 Sex, ADHD Screener Status and Cannabis Use and Abuse
4.8.1 ADHD screener status and cannabis use and abuse among men. A larger
proportion of men who screened positive for ADHD (83.33%) [64.55, 93.69] than men
who screened negative for ADHD (43.27%) [40.02, 46.57] reported using cannabis,
marijuana, or hash in their lifetime. Of all men who reported using cannabis in their
lifetime, 6.00% [4.00, 8.85] also screened positive for ADHD. Lifetime cannabis,
marijuana or hash use among men differed significantly by ADHD Screener status, χ2 (1,
N = 936) = 18.87, p = .000. Men who screened positive for ADHD were more likely to
report having used cannabis, marijuana or hash in their lifetime than men who screened
negative for ADHD (OR= 6.56; 95% CI = 2.49, 17.28). However, no significant
differences were found between men in both the positive and negative ADHD screener
groups for cannabis, marijuana or hash use over the past 12 months, χ2 (1, N = 935) =
2.15, p = .143, or over the past 3 months, χ2 (1, N = 940) = 2.21, p = .137. No significant
difference in cannabis abuse between men who screened positive for ADHD and men
who screened negative for ADHD was found, χ2 (1, N = 934) = 2.63, p = .105.
4.8.2 ADHD screener status and cannabis use among women. Of all women
who screened positive for ADHD, 65.79% [48.58, 79.86] reported using cannabis in their
lifetime compared to 35.67% [32.71, 38.74] of women who screened negative for
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ADHD. Women who screened positive for ADHD represented 6.56% [4.37, 9.66] of all
women who reported using cannabis, marijuana or hash in their lifetime. Lifetime
cannabis, marijuana and hash use among women differed significantly by ADHD
screener status, χ2 (1, N = 1036) = 14.28, p = .000, with women who screened positive for
ADHD having higher odds of lifetime cannabis, marijuana or hash use than women who
screened negative for ADHD (OR = 3.47; 95% CI = 1.75, 6.86). A larger proportion of
women who screened positive for ADHD, 26.32% [13.98, 43.39], compared to women
who screened negative for ADHD, 11.04% [9.20, 13.19], also reported using cannabis,
marijuana or hash over the past 12 months. Women who screened positive for ADHD
represented 8.33% [4.29, 15.16] of all women who reported using cannabis, marijuana or
hash in the past 12 months. Past 12 month cannabis, marijuana or hash use among
women differed significantly by ADHD screener status, χ2 (1, N = 1034) = 8.32, p = .004,
with women who screened positive for ADHD having higher odds of past 12 month
cannabis, marijuana or hash compared to women who screened negative for ADHD (OR
= 2.88; 95% CI = 1.36, 6.08). Yet no significant difference in past three month cannabis,
marijuana or hash use between women who screened positive for ADHD and women
who screened negative for ADHD was found, χ2 (1, N = 1045) = 1.53, p = .216.
4.8.3 Cannabis use among men and women who screened negative for
ADHD. Lifetime cannabis marijuana or hash use was prevalent among 43.27% [40.02,
46.57] of men and 35.67% [32.71, 38.74] of women who screened negative for ADHD.
Of those who had used cannabis, marijuana or hash in their lifetime, 52.41% [48.76,
56.03] were men and 47.59 [43.97, 51.24] were women. Past 12 month cannabis,
marijuana or hash use was prevalent among 15.93% [13.64, 18.52] of men who screened
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negative for ADHD and among 11.04% [9.20, 13.19] of women who screened negative
for ADHD. Of those who had used cannabis, marijuana or hash in the past 12 months,
56.69% [50.34, 62.83] were men and 43.31% [37.17, 49.66] were women. Past 3 month
cannabis, marijuana or hash use was prevalent among 11.21% [9.32, 13.43] of men who
screened negative for ADHD and 7.46% [5.95, 9.30] of women who screened negative
for ADHD. Of those who had used cannabis, marijuana or hash in the past 3 months,
57.63% [49.98, 64.94] were men and 42.37% [35.06, 50.02] were women. Men and
women who screened negative for ADHD were found to differ on lifetime, past 12 month
and past 3 month cannabis, marijuana or hash use, respectively (χ2 (1, N = 1904) = 11.49,
p = .001; χ2 (1, N = 1900) = 9.77, p = .002; χ2 (1, N = 1916) = 8.03, p = .005), with men
who screened negative for ADHD having higher odds of lifetime cannabis, marijuana or
hash use (OR = 1.38; 95% CI = 1.14, 1.65), past 12 month use (OR = 1.53; 95% CI =
1.17, 1.99) and past 3 month use (OR = 1.57; 95% CI = 1.15, 2.14) than women who
screened negative for ADHD.
Approximately 10.62% [8.73, 12.86] of men who screened negative for ADHD
and 7.46% [5.95, 5.30] of women who screened negative for ADHD met the cut-off for
cannabis abuse. Of those who abused cannabis, 56.14% [48.36, 63.64] were men and
43.86% [36.36, 51.64] were women. A significant difference in cannabis abuse between
men and women who screened negative for ADHD was found, χ2 (1, N = 1910) = 5.85, p
= .016, with men having higher odds cannabis abuse compared to women (OR = 1.48;
95% CI = 1.08, 2.02).
4.8.4 Cannabis use among men and women who screened positive for ADHD.
Among those who screened positive for ADHD, 83.33% [64.55, 93.69] of men and
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65.79% [48.58, 79.86] of women reported using cannabis, marijuana or hash in their
lifetime and no significant difference in lifetime cannabis, marijuana or hash use between
men and women who screened positive for ADHD was found, χ2 (1, N = 68) = 2.65, p =
.103. Regarding cannabis, marijuana or hash use over the past 12 months among those
who screened positive for ADHD, 25.81% [12.54, 44.93] of men and 26.32% [13.98,
43.39] of women endorsed using cannabis over the past 12 months and no significant
difference in past 12 month cannabis, marijuana or hash use between men and women
who screened positive for ADHD was found χ2 (1, N = 69) = 0.002, p = .962. Moreover,
20.00% [8.40, 39.13] of men and 12.82% [4.82, 28.23] of women reported using
cannabis, marijuana or hash over the past 3 months and again, no significant difference in
past 3 month cannabis, marijuana or hash use between men and women who screened
positive for ADHD was found, χ2 (1, N = 69) = 0.65, p = .419. Moreover men and
women who screened positive for ADHD did not differ in rates of cannabis abuse, χ2 (1,
N = 68) = 1.20, p = .273.
4.9 Sex, ADHD Screener Status and Lifetime Cocaine Use
4.9.1 ADHD and lifetime cocaine use among men. About 22.58% [10.28,
41.54] of men who screened positive for ADHD and 9.46% [7.67, 11.60] of men who
screened negative for ADHD reported using cocaine in their lifetime. Men who screened
positive for ADHD accounted for 7.53% [3.3.4, 15.40] of all men who had reported using
cocaine in their lifetime. Lifetime cocaine use among men differed significantly by
ADHD screener status, χ2 (1, N = 940) = 5.79, p = .016, with men who screened positive
for ADHD having higher odds lifetime cocaine use than men who screened negative for
ADHD (OR = 2.79; 95% CI = 1.17, 6.67).
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4.9.2 ADHD screener status and lifetime cocaine use among women. Among
women, 23.68% [12.02, 40.61] of those who screened positive for ADHD and 3.71%
[2.66, 5.13] of those who screened negative for ADHD had reported using cocaine in
their lifetime. Also, women who screened positive for ADHD accounted for 19.57%
[9.87, 34.38] of all women who had reported using cocaine in their lifetime. A significant
association between lifetime cocaine use among women and ADHD screener status was
found, χ2 (1, N = 1036) = 34.43, p = .000, with women who screened positive for ADHD
having higher odds of lifetime cocaine use than women who screened negative for
ADHD (OR = 8.06; 95% CI =3.56, 18.24).
4.9.3 Lifetime cocaine use among men and women who screened negative for
ADHD. In those who screened negative for ADHD, 9.46% [7.67, 11.50] of men and
3.71% [2.66, 5.13] of women reported using cocaine in their lifetime. Of all those who
reported using cocaine in their lifetime, 69.92% [60.89, 77.68] were men and 30.08%
[22.32, 39.11] were women. A significant association between sex and lifetime cocaine
use among those who screened positive for ADHD was found, χ2 (1, N = 1907) = 26.10, p
= .000, with men having higher odds of lifetime cocaine use than women (OR = 2.71;
95% CI = 1.83, 4.03).
4.9.4 Lifetime cocaine use among men and women who screened positive for
ADHD. Regarding lifetime cocaine use, 22.58% [10.28, 41.54] of men and 23.68%
[12.02, 40.61] of women who screened positive for ADHD had reported using cocaine in
their lifetime. Of those who had reported using cocaine in their lifetime, 43.75% [20.75,
69.45] were men and 56.25% [30.55, 79.25] were women. No significant difference in
lifetime cocaine use between men and women who screened positive for ADHD was
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found, χ2 (1, N = 69) = 0.01, p = .914. Results from all analyses stratified by sex and
ADHD screener status are presented in Table 4.1 below.
Table 4.1
Proportions and 95% Confidence Intervals for Variables Stratified by Sex
Variable

ADHD Positive
Men (%)
Women (%)

ADHD Negative
Men (%)
Women (%)

Previous
ADHD
Diagnosis

9.68
[2.53, 26.90]

10.26
[3.34, 25.16]

3.97
[2.83,5.51]

1.00
[0.51, 1.89]

Anti-anxiety
Med Use

30.00
[15.41, 49.56]

47.37
[31.31, 63.95]

4.51
[3.29, 6.12]

7.07
[5.60, 8.88]

Antidepressant
Med Use

25.81
[12.54, 44.93]

46.15
[30.43, 62.62]

4.29
[3.11, 5.87]

7.55
[6.03, 9.40]

Psychiatric
Distress

35.48
[19.83, 54.62]

48.72
[32.71, 64.97]

7.46
[5.88, 9.41]

9.84
[8.10, 11.89]

ASPD Screener
Status

20.00
[9.51, 37.31]

0

0.90
[0.42, 1.84]

0

Hazardous
Alcohol Use

25.81
[12.54, 44.93]

23.68
[12.02, 40.61]

18.72
[16.22, 21.50]

7.16
[5.67,8.99]

Cannabis
Lifetime

83.33
[64.55, 93.69]

65.79
[48.58, 79.86]

43.27
[40.02, 46.57]

35.67
[32.71, 38.74]

Cannabis Past
12 Months

25.81
[12.54, 44.93]

26.32
[13.98, 43.39]

15.93
[8.40,39.13]

11.04
[9.20, 13.19]

Cannabis Past 3
Months

5.56
[2.28, 12.19]

12.82
[4.82,28.23]

11.21
[9.32, 13.43]

7.46
[5.95, 9.30]

Cannabis
Abuse

20.00
[8.40, 39.13]

10.53
[3.43, 25.75]

10.62
[8.73, 12.86]

7.46
[5.95,5.30]

Cocaine
Lifetime

22.58
[10.28, 41.54]

23.68
[12.02, 40.61]

9.46
[7.67, 11.60]

3.71
[2.66, 5.13]
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Chapter 5: Hierarchical Logistic Regression Model
A logistic regression analysis was conducted to predict psychiatric distress in
1871 participants using age, sex, ASPD screener status, ADHD screener status, and
substance use as predictors. Psychiatric distress was used as a screener for anxiety and
depression. Lewis and Wessely (1990) found that the convergent validity between the
GHQ-12 (psychiatric distress) and the Hospital Anxiety and Depression Scale was 0.74.
In hierarchical logistic regression, variables are entered in steps (blocks) following
theoretical or pragmatic reasoning about the sequential order of the variables that may
predict a given outcome. Covariates were entered in three blocks as follows:
demographic variables (block 1), psychiatric variables (block 2), and substance use
variables (block 3).
Block 1 consisted of the demographic variables age and sex. These have been
found to be associated to depression and anxiety; studies have shown that anxiety and
depressive disorders are most prevalent at middle age and among women (Kroenke,
Strine, Spitzer, Williams, Berry & Mokdad, 2009; Bland, 1997; Lehtinen & Joukamaa,
1997; Kessler, McGonagle, Swartz, Blazer & Nelson, 1993). Antisocial personality
disorder (ASPD) screener status and ADHD screener status were entered in block 2.
ASPD was included in the model due to its frequent co-occurrence with ADHD (Barkley,
Fischer, Smallish, & Fletcher, 2004; Mannuzza, Klein, Bessler, Malloy, & LaPadula,
1998; Satterfield & Schell, 1997; Weiss, Hechtman, Milroy & Perlman, 1985). As such,
antisocial traits needed to be controlled for in order to isolate the effects of ADHD on
psychiatric distress. Here, ADHD was the main predictor variable of interest hence its
inclusion in the model was imperative. Additionally, according to DSM-IV-TR, ADHD is
considered a disorder of early developmental origins, while depression is considered a
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disorder of later age onset (Ostrander & Herman, 2006). Finally, hazardous alcohol use
and cannabis use were entered into the model in block 3. Frequent alcohol and cannabis
use has been shown to increase the risk of depression and anxiety and has also been
found to be associated with ADHD (Horwood et al., 2012; Boden & Ferguson, 2011;
Biederman et al., 1995; Biederman et al., 1997). As such, the nature and magnitude of
the contribution of these variables to the overall outcome was of interest.
Table 5.1 displays the results from the hierarchical logistic regression analysis for
psychiatric distress. Results from block 1 showed that the addition of the variables age
and sex added to the model (Model χ2 = 12.20, p = .002). Age accounted for about 7% of
the variance in psychiatric distress (Wald χ2 = 6.51, p = .001). Younger individuals had
higher odds of psychiatric distress than older individuals (OR = 0.99; 95% CI = 0.98,
1.00), with a 1.2% decrease in the odds of psychiatric distress with each one year increase
in age. Sex was also a significant predictor of psychiatric distress (OR = 0.68; 95% CI =
0.48, 0.92), accounting for approximately 6% of the variance between those who were
above threshold for psychiatric distress and those who were not (Wald χ2 = 5.71, p =
.017). Furthermore, females were more likely to have psychiatric distress and being
female was associated with a 31.60% increase in odds of psychiatric distress.
Psychiatric predictors were added following demographic predictors in block 2.
The addition of psychiatric predictors was significant, Block χ2 = 50.49, p = .000. ASPD
screener status did not significantly predict psychiatric distress. ADHD screener status
however was found to significantly predict psychiatric distress and accounted for about
50% of the variability in psychiatric distress in the sample (Wald χ2 = 49.84, p = .000).
Moreover, those who screened positive for ADHD had approximately 7 times the odds of
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psychiatric distress (OR= 6.85; 95% CI = 4.00, 11.72). Furthermore, with the addition of
the ADHD variable, age was no longer a significant predictor of psychiatric distress.
Two substance abuse variables, hazardous alcohol use and cannabis use were
subsequently added in block 3. This block was non-significant; hazardous alcohol use
and cannabis abuse did not significantly predict psychiatric distress, Block χ2 = 0.06, p =
.969.
A test of the full model against a constant only model was statistically significant,
indicating that the predictors as a set reliably distinguished between those who screened
positive for psychiatric distress and those who did not (Model χ2 = 62.75, p = .000, df =
6). The full model resulted in the correct classification of 89.94% of the data. The
Hosmer-Lemeshow goodness-of-fit test was greater than .05; therefore we failed to reject
the null hypothesis that there is no difference between observed and model-predicted
values, implying that the model’s estimates fit the data at an acceptable level and is wellcalibrated to predict cases from non-cases (c = 0.81). Sex and ADHD were the only two
independent predictors of psychiatric distress, as the percentage of variance accounted for
by each variable remained relatively unchanged in block 3. Sex was associated with
increased odds of psychiatric distress and ADHD was associated with roughly a
sevenfold increase in the risk of psychiatric distress.
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Table 5.1
Hierarchical Binary Logistic Regression Analysis for Psychiatric Distress (N = 1871)
Variable

β

S.E.

Wald

df

Sig.

Exp.
(β)

95% C.I.

(Constant) -2.19

.08

801.27

1

.000

0.11

Age
-.01
Sex
-.38
(Constant) -1.49

.01
.16
.23

6.51
5.71
41.52

1
1
1

.011
.017
.000

0.99
0.68
0.23

0.98, 1.00
0.50, 0.93

Age
Sex
ASPD
screen
ADHD
screen
(Constant)

-.01
-.40
.90

.01
.16
.79

3.23
5.97
1.30

1
1
1

.072
.015
.255

0.99
0.67
2.47

0.98, 1.00
0.49, 0.92
0.52, 1.64

1.92

.27

49.84

1

.000

6.88

4.03, 1.75

-1.77

.24

53.35

1

.000

0.17

Age
Sex
ASPD
screen
ADHD
screen
Cannabis
Abuse
AUDIT
8+
(Constant)

-.01
-.41
.90

.01
.17
.79

2.99
5.94
1.29

1
1
1

.084
.015
.255

0.99
0.67
2.46

0.98, 1.00
0.48, 0.92
0.52, 1.56

1.92

.27

49.30

1

.000

6.85

4.00,11.72

-.05

.28

0.04

1

.851

0.95

0.54, 1.66

.05

.25

0.46

1

.830

1.05

0.65, 1.71

-1.98

.26

46.32

1

.000

0.17

Block 0
Block 1

Block 2

Block 3

Note: Block 1 χ2 (2) = 12.20, p = .002, -2 Log likelihood = 1190.68; Block 2 χ2 (4) = 62.69, p = .000, -2
Log likelihood = 1140.19; Block 3 χ2 (6) = 62.75, p = .000, -2 Log likelihood = 1140.12.
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Chapter 6: Discussion
6.1 Findings of Interest
The purpose of this study was to estimate the prevalence and correlates of adult
ADHD in Ontario using population-based data, although it is important to point out that
the results of this study are based on self-report screening tools and not psychiatric
diagnosis. Thus, readers should be mindful that the results of this study may not reflect
actual prevalence and correlates of diagnosed ADHD in the community. That said, the
overall prevalence of adult ADHD in Ontario, using the ASRS Screener v1.1,was found
to be approximately 3.5%. This estimate is in accordance with the WHO World Mental
Health epidemiological studies that estimated the prevalence of adult ADHD to be
approximately 3.4% in the total sample using the same screening measure (Fayaad et al.,
2007; Kessler et al., 2006; Medina-Mora et al., 2005), however it is slightly lower than
population-based estimates from the U.S. also using the same measure (Kessler et al.,
2006). Approximately equal proportions of men and women screened positive for
ADHD, which is in line with earlier evidence of an equalization of the disorder between
the sexes in adulthood (Faraone & Biederman, 2005; Kessler et al., 2005; McGough et
al., 2005).
Significant age differences were found in this study. Specifically, estimates of
ADHD positive screen were highest among those 18-34 years old and declined with
increasing age. These results are in keeping with earlier studies that reported a decline of
ADHD symptoms with increasing age (Biederman et al., 2000; Faraone, Bierderman,
Spencer, Wilens, Seidman, Mick & Doyle, 2000).
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Only 10% of adults who screened positive for ADHD had previously been
diagnosed with ADHD. Another recent epidemiological ADHD study found similarly
low rates of previous ADHD diagnoses (de Zwaan, 2012). Furthermore, the vast majority
(86.25%) of those who reported previous diagnosis with ADHD was under the age of 44
and reported ADHD diagnoses were most prevalent among those aged 18-34 year old,
suggesting a cohort effect resulting from the lack of a consistent conceptualization of the
disorder throughout history. In fact, it was not until relatively recently (the early 1980s)
that objective diagnostic criteria for ADHD (then termed ADD) appeared in DSM III.
Thus, those who were school-aged prior to the 1980s were much less likely to have been
sent to a medical practitioner and even less likely to have received a diagnosis. Indeed it
is much more probable that prior to the 1980s, children who we would now consider as
having ADHD were simply labeled ‘hyperactive’, ‘defiant’ or their behaviour was
excused on the premise that ‘boys will be boys’ and that was the end of it. The low
diagnostic rate could also indicate that the ASRS Screener v1.1 is missing persons with
diagnosed ADHD.
The prevalence of adult ADHD screener status was not found to differ between
urban and rural areas as it has in previous studies that reported higher estimates of
psychopathology in urban compared to rural areas (Peen, Shoevers, Beekman & Dekker,
2010). Variations in the definitions of what constitutes “rural” and “urban” areas between
studies have been cited as a possible explanation for discrepant results in the literature (de
Zwaan, 2012). Furthermore, divergent findings regarding ADHD and urbanization
indicate that this association requires further investigation among adults.

95
A lower rate of ADHD positive screen was found among those who were married,
while a higher rate of ADHD positive screen was found among those who had never been
married. Results from the current study are consistent with those from previous
population studies (Kessler et al., 2006; de Zwaan, 2012) that have also examined the
relationship between ADHD and marital status. These studies found that not only were
those with ADHD more likely to have never been married, but they were also more likely
to be separated or divorced- a finding that was not corroborated in the current study.
Nonetheless, taken together, the tendency for those with ADHD to be less likely to be
married and more likely to be previously or never married may reflect the interpersonal
difficulties often reported in this population.
However, the effect of age must also be considered as a plausible explanation for
our finding that those with ADHD were less likely to be married, as a large proportion of
those who screened positive for ADHD were between the ages of 18 to 34 and hence are
less likely to be married due to their younger age. This cohort effect may also explain
why our study failed to support earlier work that found that those with ADHD were more
likely to be previously married. Subsequent analyses should control for the effect of age
on marital status in ADHD.
Our study did not find any differences in employment according to ADHD
screener status. These results therefore do not support the association between ADHD
and occupational challenges in adulthood found in the literature (Barkley, 2002).
Previous studies have found that those with ADHD were more likely to experience a
number of negative employment outcomes including being more likely to be terminated
from a job, frequent job changes, and lower job performance ratings (Manuzza, Klein,
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Bessler, Malloy & Hynes, 1997). However, the aforementioned studies were based on
clinical samples that may display higher levels of impairment than individuals who
screened positively with ADHD in the general population.
Moreover, the current study found that those who screened positive for ADHD
did not differ from their non-ADHD counterparts in educational attainment or annual
household income. The majority of both groups reported having some post-secondary
education or a university degree, a finding that stands in stark contrast to the general
consensus that ADHD is associated with low educational performance (Weiss et al. 1985;
Manuzza et al. 1993; Murphy, Barkley & Bush, 2002). In fact, education is generally
thought to be the area in which ADHD has the greatest impact (Barkley, 2002). Poor
educational outcomes have been corroborated by numerous studies citing that 32-38% of
those with ADHD do not complete high school, few people with ADHD enter college,
and of those who do, only about 5% graduate (Fischer, Barley, Smallish & Fletcher,
2002).
Again, the discrepancy in findings between our study and the particularly poorer
educational outcomes reported in previous studies could be due to important differences
in methodology. Mainly, these studies were follow-up reports of clinically-referred
samples and these samples, may be biased in that their impairments may be more severe
than those found in the general population. Children who are referred to clinics by their
parents and adults who are distressed to the point of seeking treatment represent only a
subset of ADHD and this subset may in all likelihood, display greater functional
impairment. On the other hand, the results of this study were based on a screening tool
and not a clinical diagnosis and thus may not be accurate in its assessment of ADHD.
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The current study used the GHQ-12 to ascertain current prevalence estimates of
psychiatric distress. A large proportion (43.48%) of those who screened positive for
ADHD also screened positive for psychiatric distress compared with 8.71% of those who
screened negative for ADHD. Furthermore, those who screened positive for ADHD had
higher odds of psychiatric distress than those who screened negative for ADHD (OR =
8.06). Men and women who screened positive for ADHD also had significantly higher
odds of psychiatric distress compared to their same sex counterparts (OR = 6.82 and 8.70
respectively) with rates being highest among women who screened positive for ADHD.
These results are consistent with previous work with referred and non-referred
groups of children, adolescents, and adults demonstrating additional mental health issues
in ADHD, particularly where mood and anxiety disorders are concerned (Biederman et
al., 1993; Kooij, Buitelaar, van den Oord, Furer, Rijnders & Hodiamont, 2004).
Furthermore, epidemiological studies have reported prevalence rates of psychiatric
distress in the general population to be around 15%, whereas the rates of psychiatric
distress are above 30% in ADHD (Shekim, Asarnow, Hess, Zaucha & Wheeler, 1990;
Biederman et al., 1991; Jensen, Shervette, Xenakis & Richters, 1993; Sobanski, 2006).
Additionally, the equalization of depression and anxiety among men and women who
screened positive for ADHD is indicative of increased psychological vulnerability
associated with the disorder and also demonstrates similarities rather than differences in
the expression of adult ADHD between sexes.
Results from our regression analysis demonstrate that ADHD contributes to a
significant proportion of the variance in psychiatric distress. Some investigators have
hypothesized that depression in ADHD is analogous to an adjustment disorder reflecting
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demoralization resulting from chronic social and academic failure (Sobanski, 2006).
Based on this theory, we speculate that ADHD and depression may be a function of the
demoralizing effects of the disorder, possibly resulting from an absence of treatment in
this population. These results are also consistent with the hypothesis that ADHD poses a
biological predisposition toward adverse environmental and social factors as well as
further mental health issues, although it is important to point out that the results of the
regression were based on a cross-sectional database; thus directionality of prediction
among variables cannot be determined.
The rates of anti-anxiety and antidepressant medication use were also notably
elevated in those who screened positive for ADHD and did not differ significantly
between sexes. A higher rate of anti-anxiety and antidepressant medication use in general
is not surprising given the correlation between ADHD and other mental health issues.
However, differential diagnosis is a prominent issue due to shared symptoms between
ADHD and many other psychiatric disorders (Milberger, Biederman, Faraone, Murphy &
Tsuang, 1995). For example, anxiety and depression often consist of symptoms of
inattention and restlessness which are hallmarks of ADHD. However, this study cannot
disaggregate ADHD from other psychiatric disorders.
The prevalence of an ASPD positive screen was significantly higher among men
who screened positive for ADHD (8.82%) than among men who screened negative for
ADHD (0.42%), however the sample size was notably small (n = 6). This finding is
supported by the results of previous longitudinal studies with children and retrospective
studies with adults that consistently report high rates of ASPD in adult ADHD and among
men in general (Weiss et al., 1985, Manuzza et al., 1993; Barkley, Fischer, Smallish, &
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Fletcher, 2004; Mannuzza, Klein, Bessler, Malloy, & LaPadula, 1998; Satterfield &
Schell, 1997; Weiss, Hechtman, Milroy & Perlman, 1985). The literature indicates that
hyperactivity and impulsivity in ADHD can lead to early conduct problems resulting in
ASPD and does predict greater delinquency and criminality in males but not in females
(Babinski, 1999). However, other authors underscore the oversimplification of the
widespread claims of poor outcomes in ADHD and of shared etiology for ADHD and
ASPD and hypothesize that the association between ADHD and ASPD is a product of the
overlap between ADHD and CD (Lilienfeld & Waldman, 1990). Hence, the association
may simply reflect the persistence of antisocial behaviour (CD) from childhood into
adulthood and not ADHD as such.
The current study also found significantly higher rates of harmful alcohol use
among those with ADHD positive screen, which is supported by previous studies that
reported a markedly higher incidence of alcohol abuse and dependence in ADHD
compared to controls (Downey et al., 1997; Biederman, Wilens, Mick, Faraone &
Spencer, 1998; Ohlmeier et al., 2008). Yet higher rates of alcohol consumption have also
been found to be associated with younger age in general (Johnson, 1998; Caetano &
Kaskutas, 1995; Fillmore, 1991) and those in the ADHD positive group were primarily of
younger age than those in the ADHD negative group. Therefore, the higher rates of
hazardous alcohol use found in this study could also be a consequence of age.
Various researchers have consistently reported an association between ADHD
and substance use disorder (SUD), with up to 50% of adults with ADHD suffering from a
concurrent SUD (Biederman et al., 1995, 1998; Wilens, Biederman, Mick, Faraone &
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Spencer, 1997). ADHD is also assumed to be associated with a twofold risk of SUD
compared to the general population.
Our results showed that individuals who screened positive for ADHD had
significantly elevated rates of lifetime and past 12 month cannabis use; however their use
over the past 3 months did not differ from those who screened negative for ADHD. These
results may suggest a propensity toward greater risk-taking behaviour in this population,
as individuals with ADHD have shown a tendency to experiment more liberally with
substance use than those without ADHD (Carroll & Rounsaville, 1993; Levin & Kleber,
1995; Wilens et al., 1997; Biederman et al., 1998). However our findings do not indicate
elevated rates of recent cannabis use, or chronic cannabis use among those who screened
positively for ADHD.
Sex-specific comparisons revealed no significant differences in hazardous alcohol
use, cannabis use, or abuse between men who screened positive for ADHD and men who
screened negative for ADHD. Women who screened positive for ADHD however had
significantly higher rates of hazardous alcohol use, as well as lifetime and past 12 month
cannabis use than women who screened negative for ADHD. Although cannabis use,
abuse, and lifetime cocaine use were more likely among men in the general population,
they did not differ significantly between men and women who screened positive for
ADHD. These results stand in contrast to earlier findings that men with ADHD have a
higher frequency of substance use than women with ADHD (Millstein, Wilens,
Biederman & Spencer, 1997; Biederman et al. 2004; McGough et al. 2005), yet they
corroborate earlier work by Biederman and colleagues (1994) indicating that ADHD
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females may share a similarly increased risk for substance use with their male
counterparts.
Although our findings showed higher odds for substance use in those who
screened positive for ADHD, the vast majority of those who screened positive for ADHD
did not engage in hazardous alcohol use (74.29%), had not used cannabis in the last year
(73.91%) or in the past 3 months (84.06%), and most were likewise not cannabis abusers
(85.29%). Many studies and reviews present a behavioural determinism perspective
whereby ADHD is presented “firmly as a biological disorder” that “has such a profound
effect on brain function that every aspect of the life of an affected individual may be
permanently compromised” (Comings et al., 2005). Yet this is not the whole story. This
perspective may be attributable to the synthesis of the findings derived principally from
highly impaired clinical samples. It would be important to examine what proportion of
those who screen positively for ADHD in the CAMH Monitor would also receive a
clinical diagnosis of ADHD, as our results show that those who screened positively for
ADHD show a propensity for psychiatric distress and greater odds of substance use yet
seem to be functioning reasonably well in areas such as education, employment, and
annual household income.
6.2 Limitations
These results however must be considered in light of the limitations inherent in
this study. Because this was a preliminary analysis of only one year of data, sample sizes
were too small for more sophisticated analyses. Importantly, age was not controlled for
because our sample did not meet the guidelines for multinomial logistic regression that
indicate a minimum of 10 cases per independent variable (Schwab, 2002). Adjusted ORs
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were not calculated in the current study and thus age may have undue influence on the
results of bivariate relationships. Therefore findings must be interpreted with caution. For
example, individuals with positive screen for ADHD had a lower likelihood of being
married and higher rates of hazardous alcohol use; yet these findings may be an artifact
resulting from the uncontrolled effect of age. Future studies using the adult ADHD
screener of the CAMH Monitor dataset should examine multiple years of data and
examine odds ratios that have been adjusted for age and sex in comparison to the crude
odds ratios presented here.
The key limitation, as previously mentioned, is that this study examined
prevalence and correlates of a number of screening tools. Subsequent research should
sample and conduct a psychiatric assessment of a cohort of participants who screened
positive and negative on the ASRS-v1.1 Screener in order to assess the sensitivity,
specificity and other important measures of degree of overlap between the screening tools
and actual psychiatric diagnoses. A related key limitation in this study was the overlap
between the items on the ASRS-v1.1 Screener and the GHQ-12 screening instruments.
The similarities between items in these screening measures make it difficult to ascertain
whether the ASRS is actually assessing ADHD symptomatology and not some
ambiguous conglomerate of psychological symptoms applicable to a wide range of
psychiatric disorders. Therefore, one cannot label those who screened positive for ADHD
with ADHDs and this fact must be taken into consideration when interpreting our
findings. Thus, the use of screening measures such as the ASRS-v1.1 Screener, the GHQ12, the AUDIT, the ASSIST and the MINI-APD as opposed to full-length assessments
and clinical diagnoses is an important methodological limitation of this study.
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Another important limitation of this work involves the generalizability of the
study results. The CAMH Monitor is only representative of non-institutionalized
Ontarians age 18 and older (n = 9,118,084 from 2001 Ontario Census) (Ialomiteanu &
Adlaf, 2007). The data collection method used in this study has several limitations,
chiefly that 1) the survey is based on households with telephones 2) the survey is based
on self-report and 3) the presence of interview barriers.
Excluded by design are Ontario households that are phoneless, which represent
1% of Ontario residents (Statistics Canada, 2011). Also excluded are those too ill or aged
to be interviewed and those unable to communicate on the telephone or in English. In
addition, household surveys are limited to those residing in conventional households and
are not intended as a sample of all possible adults. As such, those in prisons, hospitals,
military establishments, and transient populations such as the homeless are excluded.
Importantly, these excluded groups often contain an especially large number of drug and
alcohol users (Rossi, 1989). However, the coverage error depends firstly upon the
difference in drug use and mental health status between those surveyed and those not
surveyed, and secondly, the size of the group missed (Ialomiteanu & Adlaf, 2011).
Impairments may be substantially higher in the excluded group than are those in the
sampled group, yet if the size of the excluded group is small relative to the total
population, the bias is usually minimal (Kandel, 1991; Trinkoff, Ritter, & Anthony,
1990). One common deficit of telephone surveys is that they often over-represent those
with higher education and under-represent those with lower education (Trewin & Lee,
1988).
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Furthermore, survey estimates are susceptible to self- report errors that are
influenced by the conditions under which the survey is conducted. One limitation of the
CAMH Monitor in this regard is its reliance on self-reports. Reviews of self-report
methods for alcohol and drug use suggest that although surveys tend to underestimate
true usage, they are still deemed the best available method to estimate such behaviours
(Harrison, Haaga, & Richards, 1993; Turner, Lessler, & Gfroefer, 1992). One of the most
important sources of bias to consider is social desirability bias, which is the tendency of
respondents to answer questions in a manner that will be viewed favorably by others
(Krosnick, 1999).
Given that this was a preliminary assessment of adult ADHD screening status
using the first year of data collection in a multi-year study, the sample size was relatively
small. Specifically, cell counts were too low for more refined disaggregated effects and
analyses may have had insufficient power to detect statistical significance. Additionally,
missing data on the annual household income variable (> 5%) was also a limitation in this
study as imputation methods were not used to correct for this. Furthermore, the design
effect created by the 2 stage probability sampling was not accounted for in this study.
Therefore for the aforementioned reasons it is most important that caution be taken when
generalizing the results of this study to the entire population of Ontario.
6.3 Directions for Future Research
Directions for future research would include using combined data from multiple
waves of the CAMH Monitor in order to further investigate disaggregated results. Many
analyses were not possible in the current study due to the low sample size; hence
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amassing several years of data would not only improve sample size and statistical power,
but would also allow for more extensive analysis of the data.
Future research could stratify results by age group in view of providing further
insight into the similarities and differences in descriptive information, mental health
correlates and substance use across all stages of adulthood. Also, preferential drug use in
ADHD could be examined using a Canadian sample, as this was not possible due to low
cell counts for non-prescribed ADHD medication use, prescription analgesic use, opiate
use, and past year cocaine use. Furthermore, since such a small portion of the sample of
those who screened positive for ADHD had been previously diagnosed, potential studies
examining predictive factors for ADHD diagnoses are needed. Prospective follow-up
studies of young adults who screened positive for ADHD may also lend to the ASRSv1.1 as a valid predictor of ADHD, as well as ADHD as a risk factor for later outcomes.
ADHD is characterized by three symptom domains: inattention, hyperactivity and
impulsivity. The current theory of adult ADHD describes an attenuation of hyperactivity
and a persistence of inattention in adulthood. As such, the ASRS-v1.1 Screener primarily
emphasizes symptoms of inattention, with four out of the six ASRS-v1.1 Screener items
representing inattention and the remaining two items pertaining to hyperactivity.
Importantly the Screener does not contain a single item related to impulsivity. Therefore,
future studies using items representing all symptom domains are recommended. Also,
examining symptom domains in relation to demographic, psychiatric and substance use
variables may also reveal important differences between these groups. Since ADHD and
additional mental health issues display unique profiles and trajectories, comparing
outcomes between profiles would be an important priority for future research. Also,
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further studies of not only risk but resiliency factors in ADHD are also warranted.
Finally, as previously mentioned, it would be very important to conduct clinical
assessments of a cohort of respondents who screened positively and negatively on the
ASRS-v1.1 Screener, in order to determine the performance of the screener against
clinical diagnoses.

6.4 Summary and Conclusions
ADHD positive screen was significantly associated with greater rates of
psychiatric distress and antidepressant and anti-anxiety medication use. ADHD positive
screen was also found to be associated with higher rates of lifetime and past 12 month
cannabis use, however the greater majority of those who screened positively with ADHD
had not used cannabis in the past 3 months. Moreover, despite higher odds of cannabis
use disorders in ADHD, the vast majority did not screen positive for cannabis abuse.
Inconsistent with the results of previous studies, individuals who screened positively for
ADHD did not differ from those who screened negatively for ADHD in educational
attainment, employment status or annual household income. These findings are intriguing
and require further investigation.
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Appendix A Adult ADHD Self-Report Scale version 1.1
Questions
1. In the past 6 months,
have you had trouble
finishing a project?
2. In the past 6 months,
have you had difficulty
getting things in order?
3. In the past 6 months,
have you had difficulty
remembering
appointments?
4. In the past 6 months,
have you delayed projects
that required a lot of
thought?
5. In the past 6 months,
how often have you
fidgeted when sitting for a
long time?
6. In the past 6 months,
have you felt overly active
and compelled to do
things?

Never
0

Rarely
1

Sometimes
2

Often
3

Very Often
4
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Appendix B General Health Questionnaire 12 (GHQ-12)
1. Over the past few weeks, have
You been able to concentrate on
whatever you're doing?

Better than No more
usual
than usual

2. Over the past few weeks, have
you felt that you are playing a
useful part in things?

Not at all

No more
than usual

3. Over the past few weeks, have
you felt capable of making
decisions about things?
4. Over the past few weeks, have
you been able to enjoy your
normal day-to-day activities?
5. Over the past few weeks, have
you been able to face up to your
problems?

More so
than usual

Same as
usual

Rather more Much
than usual
more
than
usual
Rather more Much
than usual
more
than
usual
Less than
Much
usual
less

More so
than usual

Same as
usual

Less than
usual

Not at all

No more
than usual

6. Over the past few weeks, all
things considered, have you been
feeling reasonably happy?

Not at all

No more
than usual

7. Over the past few weeks, have
you lost much sleep because of
worry?
8. Over the past few weeks, have
you felt constantly under strain?

More so
than usual

Same as
usual

Rather more Much
than usual
more
than
usual
Rather more Much
than usual
more
than
usual
Less than
Much
usual
less

More so
than usual

Same as
usual

Less than
usual

9. Over the past few weeks, have
you felt you could not overcome
your difficulties?

Not at all

No more
than usual

10. Over the past few weeks, have Not at all
you been feeling unhappy and
depressed?

No more
than usual

11. Over the past few weeks, have Not at all
you been losing confidence in
yourself?

No more
than usual

12. Over the past few weeks, have More so
you been thinking of yourself as a than usual
worthless person?

Same as
usual

Rather more Much
than usual
more
than
usual
Rather more Much
than usual
more
than
usual
Rather more Much
than usual
more
than
usual
Less than
Much
usual
less

Much
less

Much
less
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Appendix C Antisocial Personality Disorder Module from the MINI
Neuropsychiatric Interview Version 5.0.0
Before you were 15 years old, did you:
Yes

No

2. Repeatedly lie, cheat, "con" others, or steal?

Yes

No

3. Start fights or bully, threaten, or intimidate others?

Yes

No

4. Deliberately destroy things or start fires?

Yes

No

5. Deliberately hurt animals or people?

Yes

No

Yes

No

7. Done things that are illegal even if you didn't get caught (for
example, destroying property, shoplifting, stealing, selling drugs, or
committing a felony)?

Yes

No

8. Been in physical fights repeatedly (including physical fights with
your spouse or children)?

Yes

No

9. Often lied or "conned" other people to get money or pleasure, or
lied just for fun?

Yes

No

10. Exposed others to danger without caring?

Yes

No

11. Felt no guilt after hurting, mistreating, lying to, or stealing from
others, or after damaging property?

Yes

No

1. Repeatedly skip school or run away from home overnight?

Since you were 15 years old, have you:
6. Repeatedly behaved in a way that others would consider
irresponsible, like failing to pay for things you owed, deliberately
being impulsive or deliberately not working to support yourself?
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Appendix D Alcohol Use Disorders Identification Test (AUDIT)
1. How often do you have a
drink containing alcohol?

Never

2. How many drinks do you
have on a typical day when
1 or 2
you are drinking?
3. How often do you have six
or more drinks on one
Never
occasion?
4. How often during the last
year have you found that you
Never
were unable to stop drinking
once you had started?
5. How often during the past
Never
year have you failed to do
what was normally expected of
you because of drinking?
6. How often during the past
year have you needed a drink
Never
in the morning after a night of
drinking?
7. How often during the past
year have you had a feeling of Never
remorse of guilt after
drinking?
8. How often during the past
year have you been unable to
Never
remember what has happened
the night before because of
your drinking?
9. Have you or someone else
been injured because of your
No
drinking?
10. Has a relative, friend,
doctor or other health worker
been concerned about your
No
drinking or suggested you cut
down?

Monthly
or less

2–4
times a
month

2-3 times
a week

4 or more
times a
week

3 or 4

5 or 6

7 to 9

10 or more

Less than
monthly

Monthly

Weekly

Daily or
almost daily

Less than
monthly

Monthly

Weekly

Daily or
almost daily

Less than
monthly

Monthly

Weekly

Daily or
almost daily

Less than
monthly

Monthly

Weekly

Daily or
almost daily

Less than
monthly

Monthly

Weekly

Daily or
almost daily

Less than
monthly

Monthly

Weekly

Daily or
almost daily

-

Yes, but
not in the
last year

-

Yes, but
not in the
last year

-

Yes, during
the last year

-

Yes, during
the last year
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Appendix E Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)
for Cannabis Only
1. How often have
you used cannabis,
marijuana or hash
during the PAST
THREE months?

Never
0

Once or Twice
2

Monthly
3

Weekly
4

Daily or Almost
Daily
6

2. During the PAST
3 MONTHS, how
often have you had a
strong desire or urge
to use cannabis,
marijuana or hash?

Never
0

Once or Twice
3

Monthly
4

Weekly
5

Daily or Almost
Daily
6

3. During the PAST
3 MONTHS, how
often has your use of
cannabis, marijuana
or hash led to health,
social, legal or
financial problems?

Never
0

Once or Twice
4

Monthly
5

Weekly
6

Daily or Almost
Daily
7

4. During the PAST
3 MONTHS, how
often have you failed
to do what was
normally expected of
you because of your
use of cannabis,
marijuana or hash?

Never
0

Once or Twice
5

Monthly
6

Weekly
7

Daily or Almost
Daily
8

5. Has a friend,
relative, a doctor or
anyone else ever
expressed concern
about your use of
cannabis,
marijuana or hash?

Never
0

Yes, not past 3
months
3

Yes, past 3
months
6

-

-

6. Have you ever
tried and failed to
control, cut down or
stop using cannabis,
marijuana or hash?

Never
0

Yes, not past 3
months
3

Yes, past 3
months
6

-

-
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Appendix F Diagnostic Statistics
Variable

N

Range

Min.

Age

1926

3

1

Sex

1986

1

Marital Status

1968

Education

Max.

Skewness

Kurtosis

0.895

0.059

-0.783

0.474

0.499

0.103

-1.990

3

1.518

0.813

0.109

-0.600

1

4

2.954

0.971

-.550

-0.731

7

1

8

3.250

3.203

0.784

-1.347

1986

4

1

5

3.567

1.203

-0.685

-0.423

Household
Location

1986

1

0

1

0.849

.359

-1.946

1.789

ADHD
Screening
Status

1986

1

0

1

0.035

.183

5.08

23.78

Previous
ADHD
Diagnosis

1979

1

0

1

0.030

.161

5.878

32.589

Antidepressant
Use

1980

1

0

1

0.071

0.257

3.350

9.299

Psychiatric
Distress

1986

1

0

1

0.099

0.299

2.681

5.195

ASPD
Screening
Status

1952

1

0

1

0.007

0.084

11.740

135.973

Hazardous
Alcohol Use

1937

1

0

1

0.130

0.337

2.197

2.828

M

SD

4

2.563

0

1

2

1

1970

3

Employment
Status

1977

Annual
Household
Income
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Cannabis
Lifetime

1974

1

0

Cannabis Past
12 Months

1970

1

0

Cannabis Past 3
Months

1985

1

Cocaine
Lifetime

1976

1

1

0.405

0.491

0.389

-1.351

1

0.138

0.345

2.098

2.405

0

1

0.094

0.293

2.770

5.681

0

1

0.070

0.255

3.370

9.365
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